Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Nanoparticles for mucosal vaccine delivery

Aneesh Thakur, Camilla Foged
Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

25.1 Introduction

The mucus membranes lining the surfaces of the gastrointestinal, respiratory, and genitourinary tracts and the ocular and ear cavity cover a very large surface area (approximately 400 m²) of the human body. Due to its close proximity to the external environment, the mucosa is exposed continuously to foreign substances and infectious agents. Approximately 70% of all pathogens are estimated to enter the host through the mucosa [1]. These surfaces constitute sites of extensive immunological activity. Continuous immunological monitoring conveys information to the highly specialized innate and adaptive mucosal immune system to counteract potential insults from the environment and to protect the host. Mucosal vaccines exploit the intense immunological activity associated with this administration route, and they protect against several mucosally transmitted bacterial and viral diseases [2]. To date, only a few (primarily oral) mucosal vaccines have been approved for human use, and they include the Sabin polio vaccine, vaccines against rotavirus, Salmonella typhi, and cholera, and a nasal influenza vaccine [2] (Table 25.1). These vaccines are all conventional vaccines, that is, they consist of whole pathogenic organisms, which are either killed or live attenuated. Hence, they are associated with several disadvantages, for example, tedious and expensive production, quality control and distribution, and risk of reversion to virulence. In contrast, subunit vaccines represent safer alternatives because they are based on one or several highly purified antigens of the pathogenic organisms, for example, peptides, proteins, polysaccharides, or DNA/RNA. However, the increased purity and safety are often accompanied with loss of immunogenicity, which may require addition of an adjuvant. Hence, applying subunit vaccines for mucosal immunization may overcome many of the drawbacks of conventional vaccines, but it usually necessitates the use of strong adjuvants. Adjuvants constitute a large group of structurally diverse compounds, which can generally be classified as being delivery systems or immunopotentiators, respectively, while some adjuvants possess both properties [16]. Delivery systems may enhance the immune response against an antigen via a number of different mechanisms, for example, by protecting the antigen against degradation and sustaining the release of the codelivered antigen, eventually resulting in improved vaccine efficacy. Immunopotentiators activate the immune system by being ligands for pattern-recognition receptors (PRRs) expressed by antigen-presenting cells (APCs). The advantages of administering vaccines mucosally are (i) that dual immunity is
| Disease/pathogen | Trade name | Manufacturer | Administration route/number of doses | Composition | Correlate(s) of protection | Reference |
|------------------|------------|--------------|------------------------------------|-------------|---------------------------|-----------|
| Cholera          | Vaxchora   | PaxVax, Redwood City, CA, USA Valneva Sweden AB, Solna | Oral, single dose | Live-attenuated, lyophilized CVD 103-HgR Heat- or formalin-inactivated *Vibrio cholerae* 01 Inaba and Ogawa, classic and El Tor strains, ca. $1.25 \times 10^{11} + 1\text{ mg recombinant cholera toxin B}$ | Vibriocidal antibodies Antitoxin and cholera toxin B-specific IgA | [3] |
| Dukoral           |            |              | Oral, two-three doses               |             |                           | [4] |
| ShanChol          |            | Shantha Biotecnics Ltd., India, Hyderabad | Oral, two-three doses | Heat- or formalin-inactivated *Vibrio cholerae* 01 Inaba and Ogawa, classic and El Tor strains + formalin-killed O139 bacteria | Vibriocidal and LPS-specific antibodies | [5] |
| Euvichol/Euvichol-Plus |            | EuBiologics Co., Ltd., Seoul, Republic of Korea | Oral, two-three doses | Heat- or formalin-inactivated *Vibrio cholerae* 01 Inaba and Ogawa, classic and El Tor strains + formalin-killed O139 bacteria | Vibriocidal and LPS-specific antibodies | [6] |
| Typhoid fever    | Vivotif    | PaxVax, Redwood City, CA, USA | Oral, three-four doses | Live-attenuated *Salmonella typhi* Ty21a2 | Mucosal IgA, systemic IgG, LPS-specific antibodies | [7] |
| Poliovirus        | Multiple   | Multiple      | Oral, three doses                  | Mucosal IgA, bivalent, and trivalent vaccines | Mucosal IgA, systemic IgG | [8] |
| Infectious Agent | Vaccine Name | Manufacturer | Route | Dose | Description | Immune Response | Reference |
|------------------|--------------|--------------|-------|------|-------------|----------------|-----------|
| Rotavirus | Rotarix | GlaxoSmithKline, Wavre, Belgium | Oral, three doses | Live-attenuated monovalent human rotavirus RIX4414 strain, specificity G1P | Mucosal IgA, systemic IgG | [9] |
| Rota Teq | Merck, West Point, PA, USA | Oral, three doses | Live-attenuated pentavalent rotavirus (four human strains express G1, G2, G3, G4, and P7) from bovine rotavirus. Fifth virus expresses P1A from human and G6 from bovine rotavirus | Mucosal IgA, systemic IgG | [10] |
| Rotavirus | Rotavac | Bharat Biotech, Hyderabad, India | Oral, three doses | Live-attenuated monovalent human rotavirus 116E, specificity G9P | Serum IgA | [11] |
| Rotavirus | Rotaviil | Serum Institute of India Pvt. Ltd., Pune, India | Oral, three doses | Live-attenuated bovine-human rotavirus reassortant (G1, G2, G3, G4, and G9) | Serum IgA | [12] |
| Influenza virus | FluMist | MedImmune LLC, Gaithersburg, MD, USA | Nasal, one-two doses | Live virus strain mix of one A/H1N1 strain, one A/H3N2 strain, and one B strain | Mucosal IgA, systemic IgG, possibly T cells | [13] |
| Influenza virus | FluMist Quadrivalent | MedImmune LLC, Gaithersburg, MD, USA | Nasal, one-two doses | Live virus strain mix of one A/H1N1 strain, one A/H3N2 strain, and two B strains | Mucosal IgA, systemic IgG, possibly T cells | [14] |
| Influenza virus | Nasovac-S | Serum Institute of India Pvt. Ltd., Pune, India | Nasal, one-two doses | Live-attenuated virus strains of A/H1N1, A/H3N2, and Type B influenza virus | Mucosal IgA, systemic IgG, possibly T cells | [15] |

*HN*, hemagglutinin and neuraminidase; *Ig*, immunoglobulin; *LPS*, lipopolysaccharide.
induced at mucosal and serosal sites and (ii) that immune responses are elicited both at local and distal mucosal surfaces. Moreover, mucosal vaccines possess many advantages compared with injectable vaccines, for example, ease of administration, improved patient compliance and lower costs, circumventing needle stick injuries and needle disposal, and the opportunity for mass immunization [2, 17, 18]. Table 25.2 summarizes examples of mucosal vaccine candidates in clinical trials. No mucosal adjuvants are yet available for human use, but toxin-based adjuvants are currently tested in clinical trials (Table 25.2). The purpose of this chapter is to review the current knowledge on the nanotechnology-based vaccines, which are investigated for mucosal immunization.

25.2 Organization of the mucosal immune system

The organization and function of the mucosal immune system differs from that of the systemic immune system. Hence, understanding the mucosal immune system is important in the design of novel vaccines and vaccine delivery strategies against mucosal infections. The mucosal immune system is composed of an integrated network of immune tissues and cells, constituting approximately 80% of the total immune cells of the body [19]. This myriad of immune cells is assembled in or migrates between well-organized structures, which are collectively referred to as mucosa-associated lymphoid tissue (MALT). It covers regions of the gastrointestinal tract (gut-associated lymphoid tissue [GALT]), the respiratory tract (bronchus-associated lymphoid tissue [BALT]), and the nasal cavity (nasopharynx-associated lymphoid tissue [NALT]), and it represents the largest lymphoid organ system [20]. The mucosal immune system provides three major functions: (i) detection and inhibition of the first entry of pathogenic microbes or harmful substances, (ii) prevention of uptake of ingested or inhaled antigens, and (iii) prevention of development of deleterious immune responses, if the antigens nevertheless get access to host cells. Among the immune cells, professional APCs, including dendritic cells (DCs), B cells, and macrophages, are key immune cells that surveil the mucosal surfaces. Displaying specific functions and subsets, APCs initiate adaptive immune responses and mediate vaccine-induced immunity at the mucosa. Microfold (M) cells also play a role in the transport of antigens across epithelia by transcytosis. Antigens are subsequently delivered to DCs priming the differentiation of T-cell subsets, which in turn interact with B cells, eventually resulting in the production of antibodies at mucosal sites [21, 22].

The mucosal immune system can generally be categorized into two separate compartments—inductive sites and effector sites—based on their anatomical localization and functional properties (Fig. 25.1). At the inductive sites, priming of initial immune responses takes place after antigen uptake, which leads to immune cell activation. Upon activation, antibodies and other components of the immune system exert their specific functions at the effector sites. The MALT and the associated draining lymph nodes comprise the main inductive sites for mucosal immune responses. The lamina propria of the gastrointestinal tract, the upper respiratory tract, and the female reproductive tract and the acinar regions of exocrine glands (e.g., the mammary, lacrimal, and salivary glands)
Table 25.2  Examples of mucosal vaccines in clinical trials.

| Study title                                                                 | Pathogen/condition                                      | Vaccine                                      | Administration route | Status                  | Phase | Clinical trials (government identifier) |
|-----------------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------|----------------------|-------------------------|-------|----------------------------------------|
| Evaluation of the efficacy and safety of MV130 in chronic obstructive pulmonary disease (COPD) | Recurrent respiratory tract infection in COPD patients | MV130 (Bactek), polyvalent bacterial preparation | Sublingual           | Active, not recruiting | II/III | NCT01842360                           |
| Evaluation of the efficacy and safety of MV140 (MV140)                      | Recurrent urinary tract infection                         | MV140 (Uromune), polybacterial vaccine       | Sublingual           | Recruiting              | III    | NCT02543827                           |
| A study assessing colonization and immunogenicity after nasal inoculation with *Neisseria lactamica* and eradication on day 4 or 14 | Meningitis                                               | *Neisseria lactamica*                       | Nasal               | Recruiting              | Not applicable | NCT03549325 |
| Safety and immunogenicity of the respiratory syncytial virus (RSV)          | RSV infection                                            | D46cpΔM2-2 vaccine                           | Nasal               | Active, not recruiting | I      | NCT02601612                           |
| Evaluating the infectivity, safety, and immunogenicity of the recombinant live-attenuated RSV vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-seronegative infants 6–24 months of age | RSV infection                                            | RSV ΔNS2/Δ1313/I1314L and RSV 276           | Nasal               | Recruiting              | I      | NCT03227029                           |

Continued
| Study title                                                                 | Pathogen/condition | Vaccine                                                                 | Administration route | Status       | Phase | Clinical trials (government identifier) |
|---------------------------------------------------------------------------|--------------------|-------------------------------------------------------------------------|----------------------|--------------|-------|----------------------------------------|
| Evaluating the infectivity, safety, and immunogenicity of a RSV vaccine   | RSV infection     | RSV 6120/ΔNS2/1030s                                                    | Nasal                | Recruiting   | I     | NCT03387137                            |
| (RSV 6120/ΔNS2/1030s) in RSV-seropositive children and RSV-seronegative   |                    |                                                                        |                      |              |       |                                        |
| infants and children                                                        |                    |                                                                        |                      |              |       |                                        |
| Phase I clinical trial of the safety and immunogenicity of an adenovirus-  |                    |                                                                        |                      |              |       |                                        |
| based TB vaccine administered by aerosol                                   |                    |                                                                        |                      |              |       |                                        |
| Immunogenicity of coadministered oral polio vaccine and oral cholera       |                    |                                                                        |                      |              |       |                                        |
| vaccine                                                                   |                    |                                                                        |                      |              |       |                                        |
| Monovalent oral poliovirus vaccine type 1 intestinal and humoral immunity | Poliomyelitis      | Live-attenuated poliovirus and bivalent killed whole-cell cholera vaccine | Oral                 | Recruiting   | III   | NCT03581734                            |
| study (mOPV1)                                                              |                    |                                                                        |                      |              |       |                                        |
| Trail to evaluate the immune effects of primary and booster immunizations  | Poliomyelitis      | Mono- and bivalent polio vaccine                                       | Oral                 | Recruiting   | IV    | NCT03722004                            |
| with poliovirus vaccine                                                    |                    |                                                                        |                      |              |       |                                        |
| Phase I novel live-attenuated serotype 2 oral polio vaccine study in IPV-  | Poliomyelitis      | Bivalent polio vaccine                                                 | Oral                 | Recruiting   | III   | NCT03821441                            |
| primed adults (nOPV2M4a)                                                   |                    |                                                                        |                      |              |       |                                        |
| A study to evaluate the safety and immunogenicity of novel oral polio      | Poliomyelitis      | nOPV2                                                                  | Oral                 | Recruiting   | II    | NCT03554798                            |
| vaccine                                                                   |                    |                                                                        |                      |              |       |                                        |
| Study Description                                                                                                                                                                                                 | Disease/Site                  | Vaccine/Agent                                                                 | Route | Status         | Phase | NCT Number  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-------------------------------------------------------------------------------|-------|----------------|-------|-------------|
| Extended dose intervals with oral cholera vaccine in Cameroon Effect of extended dose intervals on the immune response to oral cholera vaccine Immunologic responses to a live-attenuated oral cholera vaccine A phase II dose-ranging study of oral RV3-BB rotavirus vaccine A double-blind placebo-controlled dose escalating study to evaluate the safety and immunogenicity of dmLT by oral, sublingual, and intradermal vaccination in adults residing in an endemic area Cross-reactive immunity elicited by oral and parenteral typhoid vaccines (Ty21a-ASC) Study to evaluate the safety and immunogenicity of orally administered HIV vaccine in healthy, HIV-uninfected adult participants Multiple myeloma trial of orally administered Salmonella-based survivin vaccine (MAPSS) | Cholera                      | Killed whole-cell cholera vaccine Cholera vaccine Vaxchora RV3-BB Double mutant heat-labile toxin LT(R192G/L211A) (dmLT) Vivotif Ad4-mgag and Ad4-EnvC150 CVD908ssb-TXSVN | Oral  | Active, not recruiting Recruiting Recycling Recycling Recycling Recycling Recycling Recycling Recycling | II   | NCT03719066 NCT03373669 NCT03251495 NCT03483116 NCT03548064 NCT02121145 NCT02771730 NCT03762291 |
Fig. 25.1 See the legend on opposite page
serve as effector sites. The inductive sites provide a constant source of memory B and T cells that subsequently migrate to the mucosal effector sites via the lymphatic system, and they constitute the cellular basis for mucosal immune responses [23].

The MALT contains T- and B-cell regions and a subepithelial area rich in professional APCs, which initiate antigen-specific immune responses. M cells and epithelial cells (ECs) covering the MALT and the underlying lymphoid cells play key roles in the initiation of mucosal immune responses. M cells take up antigens from the lumen of the mucosa and transfer them to the underlying DCs, which in turn carry the antigens to the inductive sites. At the inductive sites, activation of antigen-specific B and T cells takes place. This is followed by clonal expansion and differentiation into effector B and T cells, which subsequently migrate via the lymphatics and the bloodstream into the mucosal effector sites [24]. Several T-cell subsets, including Th1, Th2, Th17, and Tregs, play important roles in regulating mucosal immune responses [25, 26]. The lamina propria serves as an effector site, and it contains antigen-specific mucosal effector cells, for example, IgA-producing plasma cells and memory B and T cells [27]. Adaptive mucosal immune responses result from CD4 T-cell help provided by CD4 Th1 or CD4 Th2 cells, which support the development of IgA-producing plasma cells. Subsequently, IgA is transported across the ECs by polymeric Ig receptors, eventually resulting in secretory IgA (sIgA) antibodies, which have specificities for various antigens encountered at

**Fig. 25.1** Immunological events at inductive and effector sites of the common mucosal immune system. Inductive and effector sites are physically separated but function in concert to protect the vast mucosal surface areas. Inductive sites are organized lymphoid tissues, and they include nasopharynx-associated, bronchus-associated, gut-associated, conjunctiva-associated, lacrimal-associated, larynx-associated, salivary duct-associated, skin-associated, vulvovaginal-associated, and rectal-associated lymphoid tissue. Effector sites represent the mucosa at the corresponding inductive sites, and they are primarily structured in the form of lymphoid follicles or tonsils. Pathogens are taken up by dendritic cells (DCs) or other types of antigen-presenting cells at the inductive sites. Pathogens ingested by DCs trigger their activation by binding to pattern-recognition receptors. Activated DCs can prime T cells present in mucosa-associated lymphoid tissue (MALT), or they migrate to the draining lymph nodes. Activated CD4 T cells differentiate into various effector CD4 T cell subsets (Teff): T helper 1 (Th1), Th2, Th17, regulatory T cells (Tregs), or follicular helper T cells (Tfh). Th2 and Tfh cells activate B cells via production of cytokines, and they induce B-cell differentiation into plasma cells, antibody class switching, and affinity maturation of antibodies, eventually leading to the development of long-lived plasma cells and memory B cells. Effector T and B cells migrate via the systemic circulation and enter the effector sites. Th1 cells activate macrophages and CD8 T cells via secretion of interferon (IFN-γ). Activated macrophages can directly engulf live pathogens and pathogens destroyed by cytotoxic T cells (CTL). Th17 cells activated by IL-23 secrete IL-17 and IL-22, which drive the production of antimicrobial peptides and the recruitment and activation of neutrophils. Tregs regulate immune responses and maintain self-tolerance by negatively regulating Th1 and Th2 cells, for example, by producing the cytokines IL-10 and transforming growth factor (TGF-β). Terminally differentiated plasma cells secrete dimeric IgA, which is subsequently transported across the epithelial cells and released as secretory IgA (sIgA). The main functions of sIgA are to prevent attachment of pathogens to epithelial cells, to neutralize viral proteins, and to remove antigens infecting the mucosa.
mucosal inductive sites, and they prevent the attachment and colonization of pathogens at mucosal surfaces [25, 28]. Other important effector mechanisms, which contribute to the host defense against pathogens at the lamina propria, include locally produced IgM and IgG and mucosal cytotoxic T lymphocytes (CTL) [29].

25.3 Routes of mucosal vaccination

In addition to the advantages of mucosal vaccination discussed above, mucosal vaccination can also induce immunity at sites distal to that of vaccine administration. This is due to the existence of an integrated cross-communication pathway of lymphoid tissues composed of inductive and effector sites, which is referred to as the common mucosal immune system (CMIS). Key effector molecules of the CMIS include IgA antibodies and cytokines, chemokines, and their corresponding receptors [25]. Mucosal vaccines can be administered via oral, nasal, pulmonary, rectal, vaginal, ocular, sublingual, or transcutaneous routes. However, only the oral and nasal routes are applied clinically for the licensed mucosal vaccines [2]. Key benefits of oral immunization include ease of immunization and delivery of particulate antigens, which induce substantial antibody responses not only in the small intestine (mostly the proximal intestine) and the ascending colon but also in the mammary and salivary glands via the CMIS [30]. Disadvantages of the oral route of immunization include exposure of the antigens to the acidic environment in the stomach and enzymatic degradation in the gastrointestinal tract. Nasal immunization results in induction of antibody responses in the mucosa of the upper airways and in saliva and nasal secretions. The nasal administration route is less hostile for antigens than oral administration, and vaccination via this route has been shown to result in faster induction of immunity and long-term memory than oral immunization due to the dense DC population present in the NALT [31, 32]. Moreover, nasal immunization also results in induction of substantial IgA and IgG responses in the cervicovaginal mucosa via the CMIS, and this is exploited for vaccination against sexually transmitted diseases like chlamydia and herpes [33, 34]. In addition to the oral and nasal routes, the pulmonary, rectal, vaginal, ocular, sublingual, and transcutaneous routes are under investigation for mucosal vaccine administration. Rectal and vaginal immunization have been shown to evoke strong local antibody responses but weak responses at distal sites of the CMIS, and they are associated with poor patient compliance [35]. The sublingual route is widely used to administer sublingual immunotherapy (SLIT) for treatment of type 1 (allergic) hypersensitivity, and T-cell proliferation and allergen-specific IgA are induced when this route of administration is applied [36]. In addition, the use of this route for vaccination against bacterial and viral pathogens has been explored in several studies [37–39]. The pulmonary administration route has gained increasing attention for vaccine delivery because of the large surface area of the lungs and the APC-rich pulmonary mucosa, and it has been investigated for vaccination against a number of respiratory pathogens [40–43]. The ocular conjunctiva represents an alternative mucosal immunization route against bacterial [44, 45] and viral infection [46], and ocular administration results in induction of immune responses locally and in the vaginal mucosa via the CMIS [44]. Transcutaneous immunization is an attractive administration route for mucosal vaccination due to the presence of a dense population
of DCs in the epidermis and dermis layers of the skin, which allow for efficient antigen uptake and subsequent induction of immune responses. Techniques used for transcutaneous vaccine delivery include iontophoresis [47], elastic liposomes [48], and microneedle patches [49].

25.4 Barriers to mucosal vaccine delivery

Commonly used vaccination methods, that is, injections, target the systemic immune system and elicit only weak mucosal immune responses. In contrast, vaccine administration directly onto mucosal sites has been shown to efficiently potentiate both mucosal and systemic immunity. However, a number of challenges are associated with successful induction of immunity in the mucosa. One of them is that vaccine antigens delivered through the mucosa tend to become diluted in mucosal secretions, which may limit effective deposition onto the mucosal epithelia [50]. In addition, antigens delivered through the mucosa have a tendency to be captured within the mucus and subsequently be degraded by proteases or nucleases [50]. The acidic environment of the gastrointestinal tract is also a barrier for successful oral immunization. Mucosal tissues are abundantly colonized by commensal microbes, which can significantly influence mucosal immune regulation and serve as a barrier to optimal mucosal immunity [51]. Mucosal or oral tolerance represents another major challenge for induction of protective immunity upon mucosal immunization [52].

Subunit vaccine formulations containing peptides, proteins, DNA/RNA, or polysaccharides are prone to degradation and may lose their biological effect during passage through the mucosa. Hence, they need adequate protection for optimal efficacy. It is now well recognized that mucosal vaccines might be more efficacious, if they mimic the physicochemical properties of opportunistic pathogens, in particular with respect to shape, charge, and size [50, 53]. Therefore an effective vaccine design and delivery strategy for mucosal immunization should (i) overcome mucosal barriers, (ii) target mucosal APCs or M cells for adequate antigen processing and presentation and T- or B-cell activation, and (iii) modulate the kinetics of antigen and adjuvant presentation for induction of protective immunological memory responses. Nanotechnology-based drug delivery systems are capable of traversing physiological barriers of the mucosa, can efficiently target immune cells, and control antigen kinetics. Hence, these approaches provide great opportunities for the design and delivery of mucosal vaccines [53].

25.5 Nanotechnology-based solutions for mucosal vaccination

Nanotechnology-based applications are attractive for targeted delivery of vaccine antigens across the mucosal surfaces. Using nanotechnology, the solubility, stability, and surface properties of vaccine antigens and/or adjuvants can readily be tailored, and hence, nanoparticle-based drug delivery systems have recently generated great interest in the field of vaccinology [53]. Vaccine antigens can either be encapsulated in or
surface-adsorbed to nanoparticles. By encapsulation, nanoparticles permit a method of delivering antigens, which may otherwise degrade fast upon injection or induce a brief, local immune response. Conjugation of antigens onto nanoparticles allows presentation of antigens to APCs in a similar way as during a natural infection and may induce a similar immune response. A size in the nanoscale region provides a high surface area-to-volume ratio and a high diffusion rate, which is suitable for the delivery of biologics including vaccine antigens to mucosal sites like the eye, nasal or lung airway, or the gut mucosa. Additional advantages of nanoparticle-based delivery systems, as compared with conventional systems, include (i) local and targeted delivery of antigens; (ii) improved antigen presentation and processing; (iii) increased and sustained antigen concentration at the mucosa; (iv) enhanced bioavailability; and (v) immunomodulation, that is, either immunostimulation via proinflammatory cytokines or immunosuppression via antiinflammatory cytokines.

Many different types of nanoparticle-based delivery systems have been investigated for vaccine delivery to mucosal surfaces. These include liposomes, polymeric nanoparticles, lipid-polymer hybrid nanoparticles, emulsions, virus-like particles (VLPs), dendrimers, and immunostimulatory complexes (ISCOMs) (Table 25.3). Design and development of an efficient and safe delivery system does not only require an understanding of the used (bio)material but also the cargo (antigen + adjuvant), the target, and the desired immunological outcome [54]. Nanoparticles must be prepared from safe materials that are pure, nonreactive, and biocompatible [55], and they should render optimal encapsulation or conjugation, stability, and permeability and sensitivity to the local environment of the mucosa to the delivered antigen [54]. In addition, nanoparticles must protect the antigen from the harsh pH conditions or enzymatic activity of the mucosa, which can otherwise result in antigen degradation [56], and deliver the antigen to the right APCs for effective activation of the immune system [57]. Therefore an effective generation of an immune response against a vaccine antigen requires knowledge about antigen uptake and processing, release kinetics, and the mechanisms of generation of mucosal immunity, which should be integrated in the design of the nanoparticle carrier [57].

25.6 Physicochemical properties that influence the biological performance of nanoparticles

A number of physicochemical properties influence the interaction between antigen-loaded nanoparticles and immune cells and hence the subsequent immunological outcome. These properties can either trigger or block immune pathways, and they can affect the stability, efficacy, and safety of the vaccine [53, 109, 110]. Important physicochemical parameters include shape, size, hydrophobicity, surface charge, colloidal stability, solid-state characteristics, and bioadhesive properties. Particle shape plays a key role for antigen presentation by APCs and uptake by other immune cells and for the intracellular processing of particles. Ellipsoidal particles have been shown to display improved pharmacokinetics and ability to induce T-cell responses, as compared with spherical particles, due to an enhanced circulation time upon intravenous
Table 25.3  Examples of nanoparticulate drug delivery systems.

| Drug delivery system | Composition                                                                 | Antigen/pathogen                                                                 | Mucosal route              | Animal model | Immunity type | References               |
|----------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------|--------------|---------------|--------------------------|
| **Lipid-based nanoparticles** |                                                                                |                                                                                  |                            |              |               |                          |
| Liposomes            | DOTAP and dimethylaminoethyl carbamate; DDA and TDB (CAF01); CAF01 and CpG; phosphatidylcholine, cholesterol, and chitosan; DPPC, DPPS, and cholesterol; DOPC and cholesterol | *Streptococcus pneumonia*; *Leishmania amazonensis* antigens; streptococcal C5a peptidase, Ag85B; influenza A virus; *Salmonella enteritidis*; H56 | Nasal, oral, sublingual, pulmonary | Mice         | IgA, IgG, Th17; IFN-γ; IgA and Th7; Th1; IgA and IgG | [41, 58–64]               |
| ICMVs                |                                                                                   |                                                                                   |                            |              |               |                          |
| Solid lipid nanoparticles |                                                                                   |                                                                                   |                            |              |               |                          |
| Cubosomes            |                                                                                   |                                                                                   |                            |              |               |                          |
| Emulsions            |                                                                                   |                                                                                   |                            |              |               |                          |
| ISCOMs               | Phosphatidylcholine, cholesterol, antigen, Quil A                                 |                                                                                   |                            | Mice         | IgG and IgA; Th1 | [73, 74]                 |

Continued
| Drug delivery system | Composition | Antigen/pathogen | Mucosal route | Animal model | Immunity type | References |
|----------------------|-------------|------------------|---------------|--------------|---------------|------------|
| **Natural polymer-based nanoparticles** | | | | | | |
| Chitosan | Mannosylated chitosan, chitosan, trimethyl chitosan | *Mycobacterium tuberculosis* Hsp65, swine influenza A virus, hepatitis B, Group A *Streptococcus* Group A *Streptococcus*, influenza A virus | Nasal | Mice, pigs | IgA, Th1; IgA, IgG, and Tem | [75–79] |
| Gamma polyglutamic acid | Polyglutamic acid and trimethyl chitosan, polyglutamic acid, chitosan, and cholera toxin subunit A1 | | Nasal | Mice | IgA and IgG; Th1 and Th2 | [79–81] |
| Hyaluronic acid | Hyaluronic acid microspheres (HYAFF) and enterotoxin from *Escherichia coli* (LT), DOTAP and hyaluronic acid | Influenza hemagglutinin, ovalbumin | Nasal | Mice, rabbits, micropigs | IgA and IgG; IgG and CD8+ T cells | [82, 83] |
| Pullulan | Cholesteryl group-bearing pullulan; TNF-α and cholesteryl group-bearing pullulan | *Clostridium botulinum* type-A neurotoxin, *Streptococcus pneumonia*, influenza A virus | Nasal | Mice, macaques | IgA and IgG; Th2 and Th17; IgG1 and IgA | [84–86] |
| **Synthetic polymer-based nanoparticles** | | | | | | |
| PLGA | PLGA and MPLA; PLGA, DDA, and MPLA; PLGA and MPL; PLGA and hydroxypropyl methylcellulose phthalate; PLGA and Eudragit; PEG and PLGA | Ovalbumin; HspX/EsxS fusion protein of *Mycobacterium tuberculosis*, H5N1 influenza; *Helicobacter pylori*, HIV envelop protein, Hepatitis B | Oral, nasal, colorectal | Mice | IgG and IgA; IgA, Th1 and Th17; IgA and Th1 | [87–91] |
| PEI | Polyethyleneimine, polyethyleneimine-triethyleneglycol, deacetylated PEI | H7N9 Influenza, HIV gag, HIV envelop protein | Nasal | Mice, chickens | IgG, IgA, Th1 and Th2: IgG, Th1, CTL; [92–94] |
| PCL | poly-e-caprolactone, PCL and chitosan, PCL and PEI, or PCL and PEG | Hepatitis B, ovalbumin, Streptococcus equi | Nasal | Mice | IgG and IgA; [95–98] |
| PPS | Polypropylene sulfide; Pluronic-stabilized PPS | Ovalbumin, H1N1 influenza | Nasal | Mice | IgG and IgA; CTL [99, 100] |
| Dendrimers Lipid-polymer hybrid nanoparticles | G4-PAMAM-NH₂ DOTAP and hyaluronic acid; PLGA, CAF01, and chitosan; PLGA, DOPC, DOTAP, and DSPE-PEG | HIV-1 gp120 Yersinia pestis, Chlamydia trachomatis, HIV-1 gag | Nasal | Mice | IgG and IgA; IgG and CD8+ T cells; IgG and IgA [101] |
| VLPs | H1N1 influenza, phosphatidylcholine, and phosphatidylethanolamine; DCPC, respiratory syncytial virus; H5N1 Influenza | HIV-1 gp41, respiratory syncytial virus, H5N1 Influenza | Nasal | Nonhuman primates, mice | IgA, IgG, antibody-dependent cell cytotoxicity; Th1 [104–106] |
| Gas-filled microbubbles | Salmonella enterica typhimurium, ovalbumin | | Nasal | Mice | IgA, Th1, and Th17 [107, 108] |

CAF01, cationic adjuvant formulation 01; CpG, cytosine-phosphodiester-guanine; CTL, cytotoxic T lymphocytes; DCPC, dicaproylphosphatidylcholine; DDA, dimethyldioctadecylammonium; DOPC, dioleoylphosphatidylcholine; DOTAP, dioleoyltrimethylammonium propane; DPPC, dipalmitoylphosphatidylcholine; DPPS, dipalmitoylphosphatidylserine; DSPC, distearoylphosphatidylcholine; DSPE, distearoylphosphatidylethanolamine; HIV, human immunodeficiency virus; HN, hemagglutinin and neuraminidase; ICMVs, interbilayer cross-linked multilamellar vesicles; IFN, interferon; Ig, immunoglobulin; ISCOMs, immunostimulatory complexes; LT, heat labile toxin; MPB, maleimidophenylbutyramide; MPL or MPLA, monophosphoryl lipid A; PCL, poly e-caprolactone; PEG, polyethylene glycol; PEI, polyethyleneimine; PLGA, poly(lactic-co-glycolic acid); PPS, polypropylene sulfide; TDB, trehalose dibehenate; Tem, effector memory T cells; Th, helper T cells; VLPs, virus-like particles.
administration [111]. Spherical particles display increased propensity for phagocytosis, as compared with more elongated shapes [112]. The size of nanoparticles does also affect their interaction with immune cells and their circulation time. Nanoparticles in the size range between 20 and 100 nm administered systemically display prolonged circulation time, as compared with smaller or larger particles [113]. Recent work shows that 50-nm particles are more efficiently taken up by DCs in the pulmonary mucosa and induce costimulatory signals, as compared with 500-nm particles, which are primarily taken up by alveolar macrophages [114]. In another study, small (approximately 190 nm in diameter) spherical particles were shown to induce Th1-biased immune response, while long (approximately 1.5 µm in length) rod-shaped particles induce Th2-biased response [115]. The surface chemistry, for example, surface charge and hydrophobicity, also plays an important role for the cellular processing of nanoparticles. Particles with a negative surface charge display reduced uptake by APCs and consequently induce weaker adaptive immune responses [116]. With increased surface charge of the nanoparticles, the uptake by APCs is increased [117]. Following interaction with the biological milieu, hydrophobic nanoparticles are coated by adsorption of plasma proteins, which prime the nanoparticles for clearance by the reticuloendothelial system [118]. In contrast, hydrophilic particles display prolonged circulation half-life in vivo [119]. Moreover, lipophilic particles easily cross cellular membranes; hence, nanoparticle carriers with both hydrophilic and lipophilic properties are suitable for mucosal antigen delivery. The colloidal stability also affects the cellular interaction, as nanoparticle suspensions can aggregate over time and become internalized by mononuclear cells [120]. For polymeric nanoparticles, additional factors should be considered during formulation of vaccines, for example, the glass transition temperature, crystallinity, and bioadhesiveness. Above the glass transition temperature, there is an increased molecular mobility and free volume of amorphous polymers, which increases the release of loaded cargo from polymers [121]. The amorphous content of polymers correlates with a high antigen release, whereas the crystalline state results in decreased release rate of the loaded antigen [121, 122]. Inclusion of bioadhesive polymers, for example, chitosan, hyaluronic acid, carboxymethyl cellulose, and sodium alginate, enhances the interaction and prolongs the contact time with the mucosal surfaces, and hence, these drug delivery systems are efficient for targeting drugs to specific cells or intracellular compartments within the mucosa [123]. Thus the physicochemical properties of nanoparticle-based drug delivery systems are important, and customizing these properties represents a unique opportunity for tailoring the interaction with immune cells and the specific type of immune response, which is elicited.

25.7 Nanoparticle-based delivery systems for mucosal vaccines

25.7.1 Lipid-based nanoparticles

Liposomes have been investigated extensively for drug delivery applications, and they show great promise for the delivery of vaccine antigens beyond the mucosal
membranes. Liposomes are usually composed of phospholipids based on natural lipids of biomembranes. Liposome vesicles consist of one or several concentric phospholipid bilayers forming uni- or multilamellar vesicles, respectively, with an inner aqueous core [124]. Both the inner aqueous core and outer bilayer membrane of liposomes are suited for delivering hydrophilic or lipophilic cargoes, respectively [124]. Liposomes are considered as proficient carriers of antigens through several mucosal membranes, and they constitute highly versatile carriers because their composition and physicochemical properties can be tailored according to the desired immune response. For example, cationic liposomes can be customized for complexation and delivery of antigens based on peptides, proteins, plasmid DNA, or mRNA, and pH-sensitive liposomes can be tailored for pH-activated release of bioactive agents [125]. In addition, the liposome surface can be decorated with, for example, ligands for specific cell targeting, bioadhesives, polyethylene glycol (PEGylation), and mannose derivatives, and they can be incorporated with toll-like receptor (TLR) ligands, other PRR ligands, and immunoglobulins for their efficient delivery of encapsulated or conjugated antigens [64, 126, 127].

Liposomes have been investigated for mucosal delivery of vaccines directed against many infectious diseases [128], and a number of liposome-based subunit vaccines are currently being tested in clinical trials [124]. Immunization with liposome-based vaccines via the nasal route has been evaluated extensively and shown to induce robust mucosal immune responses and protection against a variety of pathogens. For example, cationic liposomes based on dioleoyltrimethylammoniumpropane (DOTAP) and dimethylaminoethane-carbamoyl (DC) cholesterol were found to induce strong immune responses against the model protein antigen ovalbumin (OVA) in the nasal mucosa [129–131]. Recently, it was shown that the nasal immunity induced by these liposomes confers significant protection against infection with Streptococcus pneumonia [58]. Cationic adjuvant formulation 01 (CAF01), which consists of liposomes composed of dimethyldioctadecylammonium (DDA) and trehalose dibehenate (TDB), is another prominent example of an adjuvant, which induces mucosal immunity and protection. CAF01 has been evaluated in several animal models of infection, for example, influenza [132], Chlamydia trachomatis [33, 133], Leishmania [59], Streptococcus [60], and Mycobacterium tuberculosis [61]. In addition to nasal delivery, administration of liposomes via other mucosal routes has been investigated for vaccine delivery [41, 62, 64]. Oral administration of liposomal vaccines has been shown to induce protective mucosal immunity against influenza [62, 127] and Salmonella infection [63]. Vaccine stability in the acidic environment of the gut following oral delivery is of concern. However, this challenge can be overcome by incorporating mannose [127], galactose [134], chitosan [126], or PEG [135] for targeted delivery through the mucosa of the gastrointestinal tract. Sublingual [64] and intrapulmonary immunization [41] represent additional potentially beneficial routes for mucosal administration of liposome-based vaccines, which needs further investigation.

Liposomes have been surface-modified with polymers for efficient mucosal delivery of vaccine antigens. For example, liposomes modified with the pH-sensitive fusogenic polymer 3-methyl-glutarylated hyperbranched poly(glycidol) or succinylated poly(glycidol) induced humoral and cellular mucosal immunity [136, 137].
Up on additional incorporation of the TLR-9 ligand cytosine-phosphodiester-guanine (CpG) DNA into these liposomes, they induced even stronger immune responses and antitumor effects [138]. In a separate study, CAF01-modified poly(lactic-co-glycolic acid) (PLGA) nanoparticles induced strong antibody and Th1-type immune responses against a C. trachomatis antigen delivered mucosally [102].

Another category of lipid-based nanoparticles that is studied for mucosal vaccine delivery is interbilayer cross-linked multilamellar vesicles (ICMVs), which are formed by cross-linking the lipid headgroups of multilayered liposomes [139]. Antigens adjuvanted with ICMVs were found to prime 13-fold more CD8+ T cells than soluble antigens and induced long-lived memory T cells in both the lungs and vaginal mucosa following pulmonary administration [42].

Solid lipid nanoparticles represent another class of lipid-based nanoparticles, which can be used to deliver vaccine antigens across the mucosa. Solid lipid nanoparticles have been used for rectal delivery of hepatitis B antigen, and strong systemic and robust mucosal immunity was induced, as compared with parenteral immunization [65]. Recently, these nanoparticles were encapsulated in enteric-coated minicapsules, which induced significant immunity against hepatitis B virus [66]. Cubosomes composed of multiple lipid bilayers with aqueous channels represent another type of lipid-based nanoparticles, which have been explored as vaccine delivery systems [140]. Recently, cubosomes were used to deliver antigen across the oral mucosa [67, 68].

Emulsions, prepared by dispersing two immiscible liquids, either water-in-oil (w/o) or oil-in-water (o/w) emulsions stabilized with an amphiphilic surfactant, are able to deliver vaccine antigens through the mucosal surfaces [141]. Soybean oil [142] and squalene are the most commonly used oils for preparing emulsions [143]. The w/o emulsions integrate and more efficiently deliver hydrophilic drugs than o/w emulsions, which are used to encapsulate and deliver hydrophobic drugs [141]. The controlled release characteristics of emulsions are defined by their physicochemical properties, for example, the viscosity of the oil phase, the ratio of oil-to-water phase, and the droplet size [141]. Freund’s vaccine adjuvants are classic examples of emulsion-based adjuvants, which have been used as a standard to develop new vaccine adjuvants. The squalene-based o/w emulsions MF59 and AS03 are widely used adjuvants, which have been approved for commercial use since 1997 and 2009, respectively, for influenza vaccines [144]. Nanoemulsions have been used to induce neutralizing serum antibodies and produce a Th1- and Th17-biased cellular immunity in the mucosa against vaccine antigens of anthrax [145], influenza virus [69], human immunodeficiency virus (HIV) [72], hepatitis B virus [142], and respiratory syncytial virus [70]. In another study a nanoemulsion-adjuvated vaccine was developed to induce systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection [71]. In addition to single emulsions, double emulsions have been used to deliver antigens through the mucosa, and the double emulsion technology was found to preserve the antigen and stabilize the formulation during the emulsification process more efficiently than the single emulsion method [141]. Recently, MF59-based cationic nanoemulsions were used for nonviral delivery of self-amplifying mRNA vaccines expressing HIV [146] or influenza antigens [147].
Nanoparticles for mucosal vaccine delivery 621

Immunostimulatory complexes (ISCOMs) are spherical, micellar, and particulate antigen delivery systems of approximately 40 nm in size, which are composed of antigen, cholesterol, phospholipid, saponin, and the adjuvant Quil A [148]. ISCOMATRIX is a similar particulate adjuvant system but without the antigen. Both delivery systems have been approved for veterinary vaccines and are undergoing clinical testing in humans [149]. ISCOMs have been extensively used for delivering vaccine antigens through mucosal surfaces. Using ISCOMs with a fusion of cholera toxin and the S. aureus protein A (CTA1-DD) administered orally or nasally, strong cell-mediated and humoral immune responses, including local mucosal IgA, were induced against OVA peptide epitopes [150]. Using the same formulation, it was shown that CTA1-DD/ISCOMs when combined with major outer membrane protein of C. trachomatis stimulated CD4+ T-cell immunity and protected against C. trachomatis infection in the genital tract [151]. Strong humoral and cellular mucosal immune responses were also observed against hepatitis B antigen [152], plasmid DNA of Haemophilus influenzae [153], and palmitoylated diphtheria toxin [74] administered orally or nasally with ISCOMs. In another study, loading of the M. tuberculosis antigen 85 complex into ISCOMs significantly improved humoral and cellular immune responses after intrapulmonary immunization in mice [154]. ISCOMATRIX was reported to be an effective adjuvant for inducing mucosal immunity against influenza [155] and human T-cell lymphotropic virus type 1 [73].

25.7.2 Nanoparticles based on natural polymers

Chitosan is a natural linear polysaccharide isolated primarily from the exoskeleton of crustaceans, and its properties are well documented, including high biocompatibility and biodegradability. In addition, chitosan has mucoadhesive properties, which are attractive for mucosal vaccine delivery. Chitosan has been extensively investigated for delivery of vaccine antigens across the mucosal surfaces in several preclinical animal models of infection, for example, tuberculosis [75], influenza [76], and chlamydia [102]. However, chitosan displays low solubility under physiological conditions, which limits its use for biomedical applications [156]. To overcome this drawback a number of chitosan derivatives have been developed, including trimethyl chitosan, hydroxyethyl chitosan, chitosan ester, phosphorylated chitosan, and sulfated chitosan [157]. Trimethyl chitosan is the most studied chitosan derivative for mucosal vaccine applications. Trimethylated chitosan nanoparticles have been shown to induce strong mucosal immunity against hepatitis B virus following nasal administration [77]. Recently, trimethyl chitosan-coated liposomes were shown to induce high mucosal and systemic antibody titers upon nasal administration [78] and provided protection against infection with Group A Streptococcus [79].

Gamma polyglutamic acid, which is a polypeptide composed of glutamic acid monomers, displays high water solubility and biodegradability, and it has been used for mucosal vaccine delivery. Gamma polyglutamic acid-based nanoparticles have been shown to induce protective immunity against influenza virus infection following nasal immunization [80]. In another study, poly-gamma-glutamate/chitosan nanoparticles induced protective mucosal immunity against influenza virus infection [81].
A recent study reported strong mucosal immune responses in the nasal mucosa against Group A *Streptococcus* infection using polyglutamic acid-trimethyl chitosan-based nanoparticles [79].

Hyaluronic acid is a linear polysaccharide composed of glucuronic acid and acetyl glucosamine monomers. It has high biocompatibility, biodegradability, and mucoadhesiveness, which are attractive properties for mucosal vaccine delivery. Hyaluronic acid represents a multifunctional carbohydrate mediator of immune processes because it modulates leukocyte trafficking, which leads to maturation and migration of DCs and subsequent T-cell activation [158]. Hyaluronic acid-based delivery systems have been tested for mucosal vaccine applications. Hyaluronic acid combined with heat labile toxin-based mucosal adjuvant (LTK63) was shown to induce systemic and mucosal antibody responses following nasal administration with the influenza hemagglutinin antigen [82]. In another study, nasal delivery of F1-V, which is a candidate recombinant antigen from *Yersinia pestis*, using nanoparticles composed of hyaluronic acid and cationic liposomes induced strong humoral and a balanced Th1/Th2 immune responses [83].

Pullulan is another water-soluble linear polysaccharide, which has been used for nanoparticle-based vaccine delivery systems designed to deliver antigens across the mucosa. A nanogel consisting of a cationic type of cholesteryl group-bearing pullulan formulated with *Clostridium botulinum* type-A neurotoxin induced strong tetanus toxoid-specific systemic and mucosal immune responses after nasal immunization [84]. In addition, the pullulan-based nanogels induced Th2 and Th17 cytokine responses in the serum and respiratory tract tissues of macaques after nasal coadministration with pneumococcal surface protein A [85]. In an another study, nasal administration of cholesteryl pullulan-encapsulated tumor necrosis factor-α nanoparticles provided protective immunity against influenza infection [86].

### 25.7.3 Nanoparticles based on synthetic polymers

The use of nanoparticles based on synthetic polymers has been widely explored for delivery of vaccine antigens across the mucosa, including poly(lactic acid) (PLA), poly(glycolic acid) (PGA), PLGA, polyethyleneimine (PEI), poly-ε-caprolactone (PCL), and polyphenylene sulfide (PPS). Among these, PLGA and its derivatives, which are aliphatic polyesters, are the most extensively studied delivery systems for vaccine antigens due to their safety, biodegradability, and biocompatibility [159]. Upon in vivo administration, PLGA undergoes hydrolysis into lactic acid and glycolic acid monomers, which are removed from the body via the citric acid cycle [159]. One of the characteristic features of PLGA nanoparticles is the controlled and sustained release of antigen and adjuvant over several weeks or months, which can generate effector T-cell memory responses [160]. Moreover the type of polymer used, the molecular weight, and the manipulation of physicochemical particle properties allow for the design of PLGA nanoparticles with customized release kinetics [159]. Another important feature of PLGA nanoparticles is their ability to encapsulate not only the vaccine antigen but also various ligands for PRRs, for example, TLR ligands. PLGA nanoparticles incorporating the TLR4 ligand monophosphoryl lipid A (MPLA) and
Nanoparticles for mucosal vaccine delivery

OVA were shown to induce higher mucosal IgA and IgG titers after oral administration than PLGA without MPLA [87]. In a recent study, PLGA nanoparticles prepared with MPLA induced mucosal and systemic immune responses against the HspX/EsxS fusion antigen of *M. tuberculosis* after nasal administration [88]. Oral administration of PLGA nanoparticles loaded with a TLR7 agonist, MPL, and OVA was shown to target M cells and induce mucosal IgA and serum IgG antibodies [161]. Similarly, PLGA nanoparticles prepared with the TLR9/21 agonist CpG oligodeoxynucleotide [162] or the TLR7 agonist imiquimod [163] induced strong mucosal immune responses against protein antigens. A synergistic increase in antigen-specific neutralizing antibodies against influenza virus infection [164] and protection against simian immunodeficiency virus (SIV) [165] was observed when formulating PLGA nanoparticles with both TLR4 and TLR7 agonists, as compared with nanoparticles containing antigens each of the TLR ligands alone. Moreover, combining TLR2, TLR3, and TLR9 ligands with PLGA nanoparticles has been shown to synergistically induce mucosal antiviral protection after mucosal immunization with HIV envelope peptides [166]. PLGA nanoparticles can also be rationally designed for targeted delivery of vaccine antigens across the mucosa. Oral administration of PLGA nanoparticles modified with hydroxypropyl methylcellulose phthalate HP55 was shown to promote immune protection against *Helicobacter pylori* infection by protecting the antigen from degradation in gastric acid [89]. Similarly, PLGA nanoparticle surface coating with the methacrylate-based polymer Eudragit FS30D was shown to prevent the denaturing effects of the low pH in the stomach and enzymatic destruction and protected against genitorectal HIV infection after oral immunization [90]. Other studies have reported formulating PLGA with lectin [161], claudin 4 [167], and PEGylation [168] for specific targeting of M cells in the mucosa and a corresponding increase in mucosal immune responses. PLA nanoparticles have also been used for mucosal delivery of vaccine antigens. PEG [169] and PEG-derived block copolymers of PLA [91] have been used to develop nanoparticles encapsulating antigens for mucosal delivery. Encapsulating nucleotide-binding oligomerization domain-containing protein 1 (NOD1) and NOD2 ligands in PLA nanoparticles coated with the HIV-1 gag p24 antigen enhanced systemic and mucosal immune responses after oral and nasal administration [170]. Mucosal immunization with PLA nanoparticles specifically target DCs leading to improved mucosal immunity [171].

The cationic polymer PEI has primarily been investigated for gene delivery due to its ability to form polyplexes with nucleic acids via attractive electrostatic interactions [172]. However, there is increased evidence that PEI-based nanoparticles can improve the efficacy of conventional vaccines by (i) enhancing the maturation rates of APCs; (ii) increasing the proliferation of effector cells; and (iii) stimulating the production of antibodies, cytokines, and chemokines [172]. One of the characteristic features of PEI nanoparticles is their buffering capacity, that is, the so-called proton sponge effect, under acidic conditions inside the phagolysosomes, which allows phagocytosed or endocytosed antigens to escape from the vacuole and gain entry to the cytosol and subsequent presentation on major histocompatibility complex class I molecules, which is referred to as cross presentation [173]. This improved antigen cross presentation generates strong immune responses [172, 174]. PEI nanoparticle-formulated protein
vaccines were found to induce strong mucosal immunity against influenza [92], HIV [93], and respiratory syncytial virus [175] following mucosal administration. PEI nanoparticles have been used to deliver plasmid DNA and induced strong mucosal immunity against influenza virus [176], herpes simplex virus [176], and coronavirus infection [177] and protection against HIV infection [94]. Recent studies have shown that PEI conjugated to cyclodextrin serves as an efficient carrier for nasal mRNA vaccine delivery, lymph node trafficking, and improved immune responses [178, 179]. Although PEI is proved as a potential candidate for gene delivery, the high transfection efficiency is also associated with high toxicity [180]. Hence, a number of PEI modifications have been shown to reduce its cytotoxicity while maintaining the transfection efficiency [181] and improving biodegradability [182].

PCL is a synthetic biodegradable, semicrystalline, hydrophobic, aliphatic polyester, which can be used for delivering protein-based vaccine antigens or DNA. It was shown that PCL-based nanoparticles can be used to efficiently deliver antigens through the mucosa due to its hydrophobicity and resistance to acidic pH environments [183]. In another study, PCL/PLGA copolymer-based nanoparticles were used to deliver diphtheria toxoid nasally, and they generated higher IgG antibodies than PLGA nanoparticles alone [184]. Nasal administration of PCL nanoparticles has also been shown to increase immunogenicity and mucosal immune responses against Streptococcus antigens [98]. Similarly, chitosan [95, 96] and PEG-modified [97] PCL-based nanoparticles have been used to deliver vaccine antigens through the nasal mucosa, and they elicited strong mucosal and systemic immune responses.

PPS is a synthetic, hydrophobic, and biodegradable polymer, which has been used to prepare nanoparticles for delivery of mucosal vaccines. PPS-based nanoparticles can be prepared as small as 20 nm in diameter, and they have been shown to efficiently present antigens to APCs in the draining lymph nodes [185] and activate the alternative complement pathway [186], thereby stimulating cellular and humoral immune responses. When coadministered nasally with OVA, these nanoparticles promote mucosal and systemic CTL responses, and addition of the TLR5 ligand flagellin further enhances the humoral responses in the lungs and in the vaginal and rectal mucosa [99]. However, the magnitude and quality of the mucosal immune responses after nasal immunization were shown to vary in a nanoparticle size-dependent manner [187]. In another study, PPS-based nanoparticles with CpG were shown to generate 10-fold higher frequencies of effector CD8+ T cells in lungs than CpG and antigen alone, and they induced protective immunity in lungs against influenza virus infection [100].

Dendrimers are synthetic polymers, which are three-dimensional, hyperbranched, and monodisperse structures containing a central core surrounded by branched peripheral groups and numerous functional groups on the surface [188]. Depending on the polymer used, dendrimers can be hydrophilic or hydrophobic and can incorporate the antigen inside the core or on the surface [188]. Dendrimer properties like nanoscale size, a high degree of branching, polyvalency, and water solubility make them interesting systems for delivery of antigens and nucleic acids [188]. In one study, oral administration of a rhesus C–C chemokine receptor type 5-derived cyclopeptide conjugated with tetragalloyl-d-lysine dendrimer in rhesus macaques led to a statistically significant increase in the antigen-specific stool IgA response, which had a
neutralizing activity against SIV infection [189]. Recently, intranasal administration of HIV-1 gp120 peptide complexed with fourth-generation polyamidoamine (G4-PAMAM) dendrimers was found to induce peptide-specific IgG and IgA responses in serum, nasal fluids, and vaginal washes of mice [101].

25.7.4 Lipid-polymer hybrid nanoparticles

Lipid-polymer hybrid nanoparticles (LPNs), which combine the properties of lipids and polymers, have become prominent drug delivery systems during the past few years [190]. Usually, LPNs are made up of three components: (i) an inner polymer core, which encapsulate drugs or vaccine antigens; (ii) a lipid layer covering the polymer core; and (iii) an outer PEG layer, which prolongs the in vivo circulation time and provides steric stabilization to LPNs [191]. LPNs consisting of a poly(β-amino ester) core enveloped by a phospholipid bilayer shell have been tested for mRNA-based vaccine delivery and were found to significantly enhance the expression of the reporter protein luciferase within 6h after nasal administration [103]. We have previously demonstrated engineering of LPNs comprising PLGA modified with CAF01 using a quality-by-design approach [192]. It was recently shown that these LPNs, when coformulated with chitosan, significantly increase mucosal immune responses against the recombinant C. trachomatis fusion antigen CTH522 delivered nasally, as compared with CAF01 alone [102]. In another study, nasal delivery of LPNs consisting of cationic liposomes composed of DOTAP, dioleoyl phosphatidylethanolamine, and hyaluronic acid and coloaded with the recombinant fusion protein F1-V of Y. pestis led to strong humoral immune responses with 11-, 23-, and 15-fold increases in F1-V-specific total IgG, IgG1, and IgG2c titers, respectively, and a balanced Th1/Th2 humoral immune responses [83]. Hence, LPNs possess many advantages, for example, controlled delivery, high encapsulation efficiency, adjustable drug release profile, and potential to deliver both hydrophilic and hydrophobic antigens, and they also demonstrate potential for novel therapeutic vaccine strategies [193].

25.7.5 Virus-like particles and virosomes

Virus-like particles (VLP), which are composed of viral structural proteins that self-assemble into particle structures, mimic live viruses but lack the viral genome [194]. VLPs can present viral antigens in their native conformation, and they stimulate high immune responses. Recombivax (hepatitis B virus), Gardasil (human papillomavirus), and Hecolin (hepatitis E) represent examples of VLP-based marketed vaccines [195]. A number of other VLP-based vaccines are under development. However, these vaccines often require coadministration of adjuvants to be effective. Virosomes are vaccine delivery systems, where viral membrane proteins are integrated into unilamellar vesicles, which are composed of viral and other natural or synthetic lipids [128]. Unlike VLPs, virosomes have been shown to possess intrinsic adjuvanticity [196], although addition of an adjuvant may further potentiate vaccine efficacy [197]. A number of reports describe the application of virosomes for mucosal vaccine delivery. In a simian model of HIV infection, nasal administration of HIV-1 gp41 peptide subunit
virosomes conferred full protection against a vaginal simian-HIV challenge, which correlated with mucosal IgA and IgG responses and antibody-dependent cellular cytotoxicity [104]. Immunogenicity and antiviral activity induced by the same vaccine construct were also demonstrated in a randomized phase I clinical trial [198]. Nasal and sublingual administration of virosomes adjuvanted with innate immune receptor ligands, for example, TLR2 (Pam3CsK4) and/or NOD2-ligands (L18-muramyl dipeptide), or adjuvants, for example, c-di-adenosine monophosphate, c-di-guanosine monophosphate, cholera toxin B subunit, or ISCOMs (Matrix M), were shown to protect against influenza virus and respiratory syncytial virus infections in mice by promoting mucosal and systemic humoral and cellular immune responses [105, 106]. When used to deliver plasmid DNA, virosomes induced strong Th1 immune responses and improved vaccine efficacy following nasal administration [199, 200] owing to efficient delivery of DNA to DCs by virosomes [201].

25.7.6 Gas-filled microbubbles

Gas-filled microbubbles are micron-sized spherical structures, which comprise an inert high-molecular weight gas entrapped in a lipid- or polymer-based shell, and were originally developed as ultrasound contrast agents for imaging of the blood compartment [202]. These microbubbles have also been used for delivery of antigens [203], small molecule-based active pharmaceutical ingredients [204], and nucleic acid-based therapeutics [205] due to their characteristic capability of sonoporation upon ultrasound application [206]. However, it has been shown that lipid-based microbubbles can be taken up by APCs and deliver their antigenic cargo without ultrasound application, eventually leading to T-cell activation [207, 208]. Gas-filled microbubbles can be tailored by incorporating cationic lipids or adjuvants for enhanced immunogenicity of the antigenic cargo [204], which allows their application for mucosal vaccine delivery. In a recent study, α-galactosylceramide-adjuvanted microbubbles, which displayed the Salmonella-derived SseB antigen on their surface, induced strong antibody responses in the gut following nasal administration and significantly reduced the bacterial load after Salmonella infection [107]. In another study, therapeutic nasal administration of allergen-loaded microbubbles was found to suppress experimental allergic asthma in mice and was accompanied by a decrease in eosinophils, neutrophils, and IgE in the bronchoalveolar lavage and reduced frequencies of Th2 cytokine- and IL-17-producing CD4+ T cells in the lungs [108]. The development of cationic microbubbles has further enabled noninvasive delivery of nucleic acid therapeutics in vivo via the formation of strong attractive electrostatic interactions between cationic microbubbles and nucleic acids, which protect nucleic acids from degradation by nucleases [205].

25.8 Nanoparticulate pulmonary mucosal vaccination

Nanoparticulate formulations are being engineered for pulmonary mucosal vaccination to mimic pathogens while still maintaining the safety of vaccine antigens. Although pulmonary mucosal vaccination is a promising approach for inducing protection
against respiratory infections, many technical challenges persist. These include (i) design of appropriate and safe adjuvants and vaccine formulations for pulmonary administration; (ii) identification of the region in the respiratory tract, which is optimal for vaccine delivery and induction of protective immunogenicity; (iii) optimization of particle size and aerosolization properties for pulmonary distribution; (iv) optimization of antigen dose to stimulate protective immunity and avoid induction of tolerance; and (v) engineering of affordable devices, which are optimal for preclinical and clinical pulmonary vaccine administration [209, 210]. Appropriate formulation of antigens into solid dosage forms can result in improved vaccine stability and eliminate the need for costly cold-chain storage associated with traditional liquid vaccine dosage forms. Spray drying is one of the most commonly used scalable methods to manufacture dry powder aerosolizable antigens and nanoparticulate adjuvants [211]. Using spray drying, we have previously engineered a dry powder-based formulation for inhalation of the CAF01 adjuvant, which had preserved adjuvant activity after drying [212]. We also showed that a dry powder-based formulation of the tuberculosis subunit vaccine H56/CAF01 prepared by spray drying displays preserved vaccine-induced humoral and cell-mediated immune responses, as compared with the liquid formulation [213]. Recently, we demonstrated that the H56/CAF01 vaccine induces strong lung mucosal and systemic IgA and polyfunctional Th1 and Th17 responses after parenteral prime and intrapulmonary boost immunization [41]. Similarly, dry powder-based vaccine formulations prepared by spray drying have been evaluated against influenza [214], pertussis [215], diphtheria [216], hepatitis B [217], S. pneumonia surface protein A [218], and measles [219] antigens upon pulmonary immunization. Previously a dry powder Bacillus Calmette-Guérin (BCG) vaccine prepared by spray drying displayed improved viability, as compared with a lyophilized vaccine [220], and significantly reduced bacterial burden and lung pathology upon an experimental tuberculosis challenge, as compared with the standard parenteral liquid BCG vaccine [221]. To optimize the critical quality attributes of the dry powder-based subunit vaccines, for example, particle size and aerosolization properties, a systematic quality-by-design (QbD) approach is now frequently used. Using QbD, we optimized the formulation of dry powder CAF01 [211]. Similarly, other studies have demonstrated QbD-based formulation optimization of vaccines against tuberculosis [222, 223], influenza [224], hepatitis B [225], Neisseria meningitidis serogroup B [226], and flavivirus [227]. It is known that the particle size affects the deposition site of particles delivered through inhalation, with particles below approximately 3 μm in aerodynamic diameter depositing in the alveolar region and particles above approximately 5 μm in aerodynamic diameter depositing in the conducting airways [228]. Similarly the particle size, surface charge, and surface chemistry are important parameters, which determine the uptake and trafficking of particles by APCs and the fate and dynamics of particle clearance from the lungs [229–231]. However, the regions of lung deposition of particles optimal for safety, immunogenicity, and efficacy of vaccines is not well known. In one study, deep lung deposition of a monovalent influenza vaccine is correlated with superior immune responses [232]. However, in a recent study, the site of antigen deposition was shown to be of minor relevance in inducing protection against influenza virus infection [233]. Noninvasive and high-resolution molecular imaging techniques
that are clinically translatable, for example, positron emission tomography (PET); single-photon emission tomography (SPECT); magnetic resonance imaging (MRI); or combined multiimaging modalities such as PET-CT, SPECT-CT, and PET-MRI, aim to offer the possibility of generating this knowledge [234, 235]. Using SPECT-CT, we have shown the biodistribution and pharmacokinetics of the H56/CAF01 vaccine upon pulmonary immunization in mice [41]. Similarly, SPECT-CT imaging was used for the regional distribution and quantification of inhaled particles in an aerosolized human papillomavirus (HPV) vaccine in human volunteers [236]. PET-CT imaging was used in other studies for evaluating immune responses in human patients against a prostate cancer [237] and HPV vaccine [238]. MRI has been used to track immune cell recruitment and vaccine efficacy against cancer [239, 240]. Using a QbD approach, we have recently formulated a novel gadoteridol-loaded CAF01 formulation and evaluated real-time MRI contrast enhancement of lungs in mice following intrapulmonary administration [241]. Vaccine delivery to the lungs in preclinical rodent models require an efficient device that can aerosolize the formulation and deposit the aerosols evenly in the lungs of the animals. A number of devices have been developed and tested for delivering powders to lungs in preclinical animal studies, including whole-body, intranasal, and intratracheal exposure systems [242]. Pulmonary immunizations were performed with a dry powder insufflator (Penn-Century, Inc., Wyndmoor, PA, USA) to deliver dry powder BCG vaccine [243] and a subunit tuberculosis vaccine combining cutinase-like proteins 1 and 6 and MPT83, a secreted lipoprotein antigen with the adjuvant Lipokel [244] and a whole inactivated influenza virus vaccine [43, 245], which were found to be protective against an experimental challenge. In another study, a novel aerosol generator was developed and was shown to distribute powders homogeneously in mice lungs as compared with the dry powder insufflator [246]. Recently the PreciseInhale platform (Inhalation Sciences AB, Sweden) has enabled the administration of dry powders with high accuracy and reproducibility, with low tracheal deposition [247, 248]. Despite many challenges, considerable progress has been made for developing and testing dry powder vaccines for pulmonary delivery with a growing optimism for commercializing the first aerosolized mucosal vaccine.

25.9 Conclusions and future perspectives

Nanoparticle-based drug delivery systems offer unique opportunities in the development of novel subunit vaccines and immunotherapies, as compared with conventional vaccines based on live or inactivated pathogens. A number of nanoparticle-based delivery systems for mucosal vaccination have been described, which have their own advantages and disadvantages. The new generation of mucosal vaccines, which use components of microbes to elicit an immune response, does require not only the development of novel classes of vaccine delivery systems and adjuvants but also an understanding of the mechanisms of action of existing ones. Although outstanding progress has been made in the development of nanoparticles for delivering antigens through the mucosal surfaces, challenges and unmet needs remain. Presently, targeted delivery in mucosal vaccination aims only at mucosal epithelium and can benefit from
M cell-targeted approaches. Similarly, immune correlates of mucosal adjuvant and vaccine-mediated protection are not well established, the knowledge of which can help in developing novel mucosal vaccines. The development of novel devices for noninvasive delivery and experimental testing of mucosal vaccines will greatly benefit the field. Another area of future research is the evaluation of the impact of physicochemical properties of nanoparticles on specific immune pathways in the mucosa. Finally the overarching goal of most adjuvant research is to develop new adjuvants that can be translated to clinical use. Nanotechnology offers the platform technology for exploring each of these ideas and promises the potential for the successful realization of developing novel nanoparticulate mucosal vaccines against infectious diseases, cancer, and autoimmunity.

Acknowledgments

We are grateful to the Novo Nordisk Foundation, Denmark (grant no. NNF17OC0026526), and Independent Research Fund, Denmark (grant no. DFF-4184-00422), for financial support.

References

[1] M.R. Neutra, E. Pringault, J.P. Kraehenbuhl, Antigen sampling across epithelial barriers and induction of mucosal immune responses, Annu. Rev. Immunol. 14 (1996) 275–300.
[2] J. Holmgren, A.M. Svennerholm, Vaccines against mucosal infections, Curr. Opin. Immunol. 24 (2012) 343–353.
[3] W.H. Chen, M.B. Cohen, B.D. Kirkpatrick, R.C. Brady, D. Galloway, M. Gurwith, R.H. Hall, R.A. Kessler, M. Lock, D. Haney, C.E. Lyon, M.F. Pasetti, J.K. Simon, F. Szabo, S. Tennant, M.M. Levine, Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with vibrio cholerae O1 El Tor, Clin. Infect. Dis. 62 (2016) 1329–1335.
[4] M.E. Lucas, J.L. Deen, L. von Seidlein, X.Y. Wang, J. Ampuero, M. Puri, M. Ali, M. Ansaruzzaman, J. Amos, A. Macamule, P. Cavailler, P.J. Guerin, C. Mahoudeau, P. Kahozi-Sangwa, C.L. Chaignat, A. Barreto, F.F. Songane, J.D. Clemens, Effectiveness of mass oral cholera vaccination in Beira, Mozambique, N. Engl. J. Med. 352 (2005) 757–767.
[5] D. Sur, A.L. Lopez, S. Kanungo, A. Paisley, B. Manna, M. Ali, S.K. Niyogi, J.K. Park, B. Sarkar, M.K. Puri, D.R. Kim, J.L. Deen, J. Holmgren, R. Carbis, R. Rao, T.V. Nguyen, A. Donner, N.K. Ganguly, G.B. Nair, S.K. Bhattacharya, J.D. Clemens, Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial, Lancet 374 (2009) 1694–1702.
[6] Y.O. Baik, S.K. Choi, R.M. Olveda, R.A. Espos, A.D. Ligsay, M.B. Montellano, J.S. Yeam, J.S. Yang, J.Y. Park, D.R. Kim, S.N. Desai, A.P. Singh, I.Y. Kim, C.W. Kim, S.N. Park, A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines, Vaccine 33 (2015) 6360–6365.
[7] I. Gentschev, S. Spreng, H. Sieber, J. Ures, F. Mollet, A. Collioud, J. Pearman, M.E. Griot-Wenk, J. Fensterle, U.R. Rapp, W. Goebel, S.A. Rothen, G. Dietrich, Vivotif—a ‘magic shield’ for protection against typhoid fever and delivery of heterologous antigens, Chemotherapy 53 (2007) 177–180.
Nanoengineered Biomaterials for Advanced Drug Delivery

[8] A.S. Bandyopadhyay, J. Garon, K. Seib, W.A. Orenstein, Polio vaccination: past, present and future, Future Microbiol. 10 (2015) 791–808.

[9] A.D. Steele, K.M. Neuzil, N.A. Cunliffe, S.A. Madhi, P. Bos, B. Ngwira, D. Witte, S. Todd, C. Louw, M. Kirsten, S. Aspinall, L.J. Van Doorn, A. Bouckenooghe, P.V. Suryakiran, H.H. Han, Human rotavirus vaccine Rotarix provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial, BMC Infect. Dis. 12 (2012) 213.

[10] Z. Mo, Y. Mo, M. Li, J. Tao, X. Yang, J. Kong, D. Wei, B. Fu, X. Liao, J. Chu, Y. Qiu, D.A. Hille, M. Nelson, S.S. Kaplan, Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial, Vaccine 35 (2017) 5897–5904.

[11] R. Ella, R. Bobba, S. Muralidhar, S. Babji, K.M. Vadrevu, M.K. Bhan, A phase 4, multi-centre, randomized, single-blind clinical trial to evaluate the immunogenicity of the live, attenuated, oral rotavirus vaccine (116E), ROTAVAC(R), administered simultaneously with or without the buffering agent in healthy infants in India, Hum. Vaccin. Immunother. 14 (2018) 1791–1799.

[12] N. Rathi, S. Desai, A. Kawade, P. Venkatramanan, R. Kundu, S.K. Lalwani, A.P. Dubey, J. Venkateswara Rao, D. Narayanappa, R. Ghildiyal, N. Gogtay, P. Venugopal, S. Palkar, R. Munshi, G. Kang, S. Babji, A. Bavdekar, S. Juvekar, N. Ganguly, P. Niyogi, K. Ghosh Uttam, H.S. Rajani, A. Kondekar, D. Kumbhar, S. Mohanal, M.C. Agarwal, P. Shetty, K. Antony, B. Gunnal, A. Dharmadhikari, Y. Tang, P.S. Kulkarni, J. Flores, A phase III open-label, randomized, active controlled clinical study to assess safety, immunogenicity and lot-to-lot consistency of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants, Vaccine 36 (2018) 7943–7949.

[13] R.B. Couch, R.L. Atmar, W.A. Keitel, J.M. Quarles, J. Wells, N. Arden, D. Nino, Randomized comparative study of the serum antihemagglutinin and antineuramindase antibody responses to six licensed trivalent influenza vaccines, Vaccine 31 (2012) 190–195.

[14] L.A. Grohskopf, L.Z. Sokolow, A.M. Fry, E.B. Walter, D.B. Jernigan, Update: ACIP recommendations for the use of quadrivalent live attenuated influenza vaccine (LAIV4)—United States, 2018-19 influenza season, MMWR Morb. Mortal. Wkly Rep. 67 (2018) 643–645.

[15] P.V. Nigwekar, A. Kumar, V.V. Padbidri, A. Choudhury, A.B. Chaudhari, P.S. Kulkarni, Safety of Russian-backbone trivalent, live attenuated seasonal influenza vaccine in healthy subjects: open-label, non-randomized phase 4 study, Drug Saf. 41 (2018) 171–177.

[16] L.A. Brito, D.T. O’Hagan, Designing and building the next generation of improved vaccine adjuvants, J. Control. Release 190 (2014) 563–579.

[17] O. Kammona, V. Bourganis, T. Karamanidou, C. Kiparissides, Recent developments in nanocarrier-aided mucosal vaccination, Nanomedicine (London) 12 (2017) 1057–1074.

[18] A. Srivastava, D.V. Gowda, S.V. Madhunapantula, C.G. Shinde, M. Iyer, Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles, APIMIS 123 (2015) 275–288.

[19] P.M. Smith, W.S. Garrett, The gut microbiota and mucosal T cells, Front. Microbiol. 2 (2011) 111.

[20] J. Mestecky, W. Strober, M. Russell, H. Cheroutre, B.N. Lambrecht, B. Kelsall, Mucosal Immunology, Academic Press, San Diego, 2015.

[21] S.C. Corr, C.C. Gahan, C. Hill, M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis, FEMS Immunol. Med. Microbiol. 52 (2008) 2–12.

[22] N.A. Mabbott, D.S. Donaldson, H. Ohno, I.R. Williams, A. Mahajan, Microfold (M) cells: important immunosurveillance posts in the intestinal epithelium, Mucosal Immunol. 6 (2013) 666–677.
Nanoparticles for mucosal vaccine delivery

[23] Y. Fujkuyama, D. Tokuhara, K. Kataoka, R.S. Gilbert, J.R. McGhee, Y. Yuki, H. Kiyono, K. Fujihashi, Novel vaccine development strategies for inducing mucosal immunity, Expert Rev. Vaccines 11 (2012) 367–379.

[24] J.R. McGhee, K. Fujihashi, Inside the mucosal immune system, PLoS Biol. 10 (2012) e1001397.

[25] K. Fujihashi, P.N. Boyaka, J.R. McGhee, Host defenses at mucosal surfaces, in: R.T. Rich, T.A. Fleisher, W.T. Shearer, H.W.J. Schroeder, A.J. Frew, C.M. Weyand (Eds.), Clinical Immunology Principles and Practice, fourth ed., Elsevier, Saunders, Philadelphia, PA, 2013, pp. 239–251.

[26] R. Mohamed, G.M. Lord, T-bet as a key regulator of mucosal immunity, Immunology 147 (2016) 367–376.

[27] P. Brandtzaeg, Mucosal immunity: induction, dissemination, and effector functions, Scand. J. Immunol. 70 (2009) 505–515.

[28] N.J. Mantis, N. Rol, B. Corthesy, Secretory IgA’s complex roles in immunity and mucosal homeostasis in the gut, Mucosal Immunol. 4 (2011) 603–611.

[29] N. Strbo, S. Pahwa, M.A. Kolber, L. Gonzalez, E. Fisher, E.R. Podack, Cell-secreted Gp96-Ig-peptide complexes induce lamina propria and intraepithelial CD8+ cytotoxic T lymphocytes in the intestinal mucosa, Mucosal Immunol. 3 (2010) 182–192.

[30] P. Hobson, C. Barnfield, A. Barnes, L.S. Klavinskis, Mucosal immunization with DNA vaccines, Methods 31 (2003) 217–224.

[31] B. Bernocchi, R. Carpentier, D. Betbeder, Nasal nanovaccines, Int. J. Pharm. 530 (2017) 128–138.

[32] H. Lee, D. Ruane, K. Law, Y. Ho, A. Garg, A. Rahman, D. Esterhazy, C. Cheong, E. Goljo, A.G. Sikora, D. Mucida, B.K. Chen, S. Govindraj, G. Breton, S. Meandru, Phenotype and function of nasal dendritic cells, Mucosal Immunol. 8 (2015) 1083–1098.

[33] J.E. Wern, M.R. Sorensen, A.W. Olsen, P. Andersen, F. Follmann, Simultaneous subcutaneous and intranasal administration of a CAF01-adjuvanted chlamydia vaccine elicits elevated IgA and protective Th1/Th17 responses in the genital tract, Front. Immunol. 8 (2017) 569.

[34] J. Persson, Y. Zhang, T.A. Olafsdottir, K. Thorn, T.M. Cairns, F. Wegmann, Q.J. Sattentau, R.J. Eisenberg, G.H. Cohen, A.M. Harandi, Nasal immunization confers high avidity neutralizing antibody response and immunity to primary and recurrent genital herpes in guinea pigs, Front. Immunol. 7 (2016) 640.

[35] S. Tengvall, D. O’Hagan, A.M. Harandi, Rectal immunization generates protective immunity in the female genital tract against herpes simplex virus type 2 infection: relative importance of myeloid differentiation factor 88, Antivir. Res. 78 (2008) 202–214.

[36] R.K. Viswanathan, W.W. Busse, Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses, Chest 141 (2012) 1303–1314.

[37] A.D. Curtis 2nd, K. Jensen, K.K.A. Van Rompay, R.R. Amara, P.A. Kozlowski, K. De Paris, A simultaneous oral and intramuscular prime/sublingual boost with a DNA/Modified Vaccinia Ankara viral vector-based vaccine induces simian immunodeficiency virus-specific systemic and mucosal immune responses in juvenile rhesus macaques, J. Med. Primatol. 47 (2018) 288–297.

[38] S. Bekri, P. Bourdely, C. Luci, N. Dereuddre-Bosquet, B. Su, F. Martinon, V.M. Braud, I. Luque, P.L. Mateo, S. Crespillo, F. Conejero-Lara, C. Moog, R. Le Grand, F. Anjuere, Sublingual priming with a HIV gp41-based subunit vaccine elicits mucosal antibodies and persistent B memory responses in non-human primates, Front. Immunol. 8 (2017) 63.
[39] D.I. Bernstein, M.F. Pasetti, R. Brady, A.D. Buskirk, R. Wahid, M. Dickey, M. Cohen, H. Baughman, J. El-Khorazaty, N. Maier, M.B. Sztein, S. Baqar, A.L. Bourgeois, A phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from enterotoxigenic escherichia coli (ETEC) by sublingual or oral immunization, Vaccine (2018).

[40] N.C. Bull, E. Stylianou, D.A. Kaveh, N. Pinpathomrat, J. Pasricha, R. Harrington-Kandt, M.C. Garcia-Pelayo, P.J. Hogarth, H. McShane, Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1(+) KLRG1(−) CD4(+) T cells, Mucosal Immunol. (2018).

[41] A. Thakur, C. Rodriguez-Rodriguez, K. Saatchi, F. Rose, T. Esposito, Z. Nosrati, P. Andersen, D. Christensen, U.O. Hafeli, C. Foged, Dual-Isotope SPECT/CT imaging of the tuberculosis subunit vaccine H56/CAF01: induction of strong systemic and mucosal IgA and T-cell responses in mice upon subcutaneous prime and intrapulmonary boost immunization, Front. Immunol. 9 (2018) 2825.

[42] A.V. Li, J.J. Moon, W. Abraham, H. Suh, J. Elkhader, M.A. Seidman, M. Yen, E.J. Im, M.H. Foley, D.H. Barouch, D.J. Irvine, Generation of effector memory T cell-based mucosal and systemic immunity with pulmonary nanoparticle vaccination, Sci. Transl. Med. 5 (2013) 204ra130.

[43] J. Tomar, H.P. Patil, G. Bracho, W.F. Tonnis, H.W. Frijlink, N. Petrovsky, R. Vanbever, A. Huckriede, W.L.J. Hinrichs, Adva augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge, J. Control. Release 288 (2018) 199–211.

[44] A. Inic-Kanada, M. Stojanovic, E. Marinkovic, E. Becker, E. Stein, I. Lukic, R. Djokic, N. Schuerer, J.H. Hegemann, T. Barisani-Asenbauer, A probiotic adjuvant lactobacillus rhamnosus enhances specific immune responses after ocular mucosal immunization with chlamydial polymorphic membrane protein C, PLoS One 11 (2016) e0157875.

[45] T. Barisani-Asenbauer, A. Inic-Kanada, S. Belij, E. Marinkovic, I. Stojicevic, J. Montanaro, E. Stein, N. Bintner, M. Stojanovic, The ocular conjunctiva as a mucosal immunization route: a profile of the immune response to the model antigen tetanus toxoid, PLoS One 8 (2013) e60682.

[46] A.A. Chentoufi, G. Dasgupta, A.B. Nesburt, I. Bettahi, N.R. Binder, Z.S. Choudhury, W.D. Chamberlain, S.L. Wechsler, L. BenMohamed, Nasolacrimal duct closure modulates ocular mucosal and systemic CD4(+) T-cell responses induced following topical ocular or intranasal immunization, Clin. Vaccine Immunol. 17 (2010) 342–353.

[47] D.S. Bernardi, C. Bitencourt, D.S. da Silveira, E.L. da Cruz, M.A. Pereira-da-Silva, L.H. Faccioli, R.F. Lopez, Effective transcutaneous immunization using a combination of iontophoresis and nanoparticles, Nanomedicine 12 (2016) 2439–2448.

[48] R.K. Tyagi, N.K. Garg, S.K. Dalai, A. Awasthi, Transdermal immunization of P. falciparum surface antigen (MSP-119) via elastic liposomes confers robust immunogenicity, Hum. Vaccin. Immunother. 12 (2016) 990–992.

[49] H.T.T. Duong, Y. Yin, T. Thambi, T.L. Nguyen, V.H. Giang Phan, M.S. Lee, J.E. Lee, J. Kim, J.H. Jeong, D.S. Lee, Smart vaccine delivery based on microneedle arrays decorated with ultra-pH-responsive copolymers for cancer immunotherapy, Biomaterials 185 (2018) 13–24.

[50] M.R. Neutra, P.A. Kozlowski, Mucosal vaccines: the promise and the challenge, Nat. Rev. Immunol. 6 (2006) 148–158.

[51] G.P. Donaldson, M.S. Ladinsky, K.B. Yu, J.G. Sanders, B.B. Yoo, W.C. Chou, M.E. Conner, A.M. Earl, R. Knight, P.J. Bjorkman, S.K. Mazmanian, Gut microbiota utilize immunoglobulin A for mucosal colonization, Science 360 (2018) 795–800.
Nanoparticles for mucosal vaccine delivery

[52] L. Tordesillas, M.C. Berin, Mechanisms of oral tolerance, Clin. Rev. Allergy Immunol. 55 (2018) 107–117.

[53] M.L. Bookstaver, S.J. Tsai, J.S. Bromberg, C.M. Jewell, Improving vaccine and immunotherapy design using biomaterials, Trends Immunol. 39 (2018) 135–150.

[54] S. Chadwick, C. Kriegel, M. Amiji, Nanotechnology solutions for mucosal immunization, Adv. Drug Deliv. Rev. 62 (2010) 394–407.

[55] S. Naahidi, M. Jafari, F. Edalat, K. Raymond, A. Khademhosseini, P. Chen, Biocompatibility of engineered nanoparticles for drug delivery, J. Control. Release 166 (2013) 182–194.

[56] J. Holmgren, C. Czerkinsky, Mucosal immunity and vaccines, Nat. Med. 11 (2005) S45–S53.

[57] T.G. Dacoba, A. Olivera, D. Torres, J. Crecente-Campo, M.J. Alonso, Modulating the immune system through nanotechnology, Semin. Immunol. 34 (2017) 78–102.

[58] R. Tada, H. Suzuki, S. Takahashi, Y. Negishi, H. Kiyono, J. Kunisawa, Y. Aramaki, Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice, Int. Immunopharmacol. 61 (2018) 385–393.

[59] J.M. Leal, M. Mosquini, L.P. Covre, N.P. Stagmiller, R.R. Rodrigues, D. Christensen, H.L. de Matos Guedes, B. Rossi-Bergmann, D.C. Gomes, Intranasal vaccination with killed Leishmania amazonensis promastigotes antigen (LaAg) associated with CAF01 adjuvant induces partial protection in BALB/c mice challenged with Leishmania (infantum) chagasi, Parasitology 142 (2015) 1640–1646.

[60] D. Christensen, R. Mortensen, I. Rosenkrands, J. Dietrich, P. Andersen, Vaccine-induced Th17 cells are established as resident memory cells in the lung and promote local IgA responses, Mucosal Immunol. 10 (2017) 260–270.

[61] A. Ciabattini, G. Prota, D. Christensen, P. Andersen, G. Pozzi, D. Medaglini, Characterization of the antigen-specific CD4(+) T cell response induced by prime-boost strategies with CAF01 and CpG adjuvants administered by the intranasal and subcutaneous routes, Front. Immunol. 6 (2015) 430.

[62] J. Liu, J. Wu, B. Wang, S. Zeng, F. Qi, C. Lu, Y. Kimura, B. Liu, Oral vaccination with a liposome-encapsulated influenza DNA vaccine protects mice against respiratory challenge infection, J. Med. Virol. 86 (2014) 886–894.

[63] Y. Pang, Y. Zhang, H. Wang, J. Jin, J. Piao, J. Piao, Q. Liu, W. Li, Reduction of Salmonella enteritidis number after infections by immunization of liposome-associated recombinant SefA, Avian Dis. 57 (2013) 627–633.

[64] H.S. Oberoi, Y.M. Yorgensen, A. Morasse, J.T. Evans, D.J. Burkhart, PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination, J. Control. Release 223 (2016) 64–74.

[65] K.K. Sahu, R.S. Pandey, Immunological evaluation of colonic delivered Hepatitis B surface antigen loaded TLR-4 agonist modified solid fat nanoparticles, Int. Immunopharmacol. 39 (2016) 343–352.

[66] K.K. Sahu, M. Kaurav, R.S. Pandey, Chylomicron mimicking solid lipid nanoemulsions encapsulated enteric minicapsules targeted to colon for immunization against hepatitis B, Int. Immunopharmacol. 66 (2019) 317–329.

[67] C. von Halling Laier, B. Gibson, M. van de Weert, B.J. Boyd, T. Rades, A. Boisen, S. Hook, L.H. Nielsen, Spray dried cubosomes with ovalbumin and Quil-A as a nanoparticulate dry powder vaccine formulation, Int. J. Pharm. 550 (2018) 35–44.
[68] C. von Halling Laier, B. Gibson, J.A.S. Moreno, T. Rades, S. Hook, L.H. Nielsen, A. Boisen, Microcontainers for protection of oral vaccines, in vitro and in vivo evaluation, J. Control. Release 294 (2018) 91–101.

[69] S.C. Das, M. Hatta, P.R. Wilker, A. Myc, T. Hamouda, G. Neumann, J.R. Baker Jr., Y. Kawakoa, Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine, Vaccine 30 (2012) 6871–6877.

[70] J.J. O’Konek, P.E. Makidon, J.J. Landers, Z. Cao, C.A. Malinczak, J. Pannu, J. Sun, V. Bitko, S. Ciotti, T. Hamouda, Z.W. Wojcinski, N.W. Lukacs, A. Fattom, J.R. Baker Jr., Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats, Hum. Vaccin. Immunother. 11 (2015) 2904–2912.

[71] H. Sun, C. Wei, B. Liu, H. Jing, Q. Feng, Y. Tong, Y. Yang, L. Yang, Q. Zou, H. Zeng, Induction of systemic and mucosal immunity against methicillin-resistant Staphylococcus aureus infection by a novel nanoemulsion adjuvant vaccine, Int. J. Nanomedicine 10 (2015) 7275–7290.

[72] A.U. Bielinska, K.W. Janczak, J.J. Landers, D.M. Markovitz, D.C. Montefiori, J.R. Baker Jr., Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates, AIDS Res. Hum. Retrovir. 24 (2008) 271–281.

[73] M. Kabiri, M. Sankian, M. Hosseinpour, M. Tafaghodi, The novel immunogenic chimeric peptide vaccine to elicit potent cellular and mucosal immune responses against HTLV-1, Int. J. Pharm. 549 (2018) 404–414.

[74] A. Aguila, A.M. Donachie, M. Peyre, C.P. McSharry, D. Sesardic, A.M. Mowat, Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine, Vaccine 24 (2006) 5201–5210.

[75] M. Wu, H. Zhao, M. Li, Y. Yue, S. Xiong, W. Xu, Intranasal vaccination with mannosylated chitosan formulated DNA vaccine enables robust IgA and cellular response induction in the lungs of mice and improves protection against pulmonary mycobacterial challenge, Front. Cell. Infect. Microbiol. 7 (2017) 445.

[76] S. Dhakal, S. Renu, S. Ghimire, Y. Shaan Lakshmanappa, B.T. Hogshead, N. Feliciano-Ruiz, F. Lu, H. HogenEsch, S. Krakowka, C.W. Lee, G.J. Renukaradhy, Mucosal immunity and protective efficacy of intranasal inactivated influenza vaccine is improved by chitosan nanoparticle delivery in pigs, Front. Immunol. 9 (2018) 934.

[77] M. Tafaghodi, V. Saluja, G.F. Kersten, H. Kraan, B. Slutter, J.P. Amorij, W. Jiskoot, Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: impact of formulation on physicochemical and immunological characteristics, Vaccine 30 (2012) 5341–5348.

[78] N. Marasini, K.A. Ghaffar, A.K. Giddam, M.R. Batzloff, M.F. Good, M. Skwarczynski, I. Toth, Highly immunogenic trimethyl chitosan-based delivery system for intranasal lipopeptide vaccines against group A streptococcus, Curr. Drug Deliv. 14 (2017) 701–708.

[79] R.J. Nevagi, Z.G. Khalil, W.M. Hussein, J. Powell, M.R. Batzloff, R.J. Capon, M.F. Good, M. Skwarczynski, I. Toth, Polyglutamic acid-trimethyl chitosan-based intranasal peptide nano-vaccine induces potent immune responses against group A streptococcus, Acta Biomater. 80 (2018) 278–287.

[80] S. Okamoto, M. Matsuura, T. Akagi, M. Akashi, T. Tanimoto, T. Ishikawa, M. Takahashi, K. Yamanishi, Y. Mori, Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice, Vaccine 27 (2009) 5896–5905.
Nanoparticles for mucosal vaccine delivery

[81] M.Y.E. Chowdhury, T.H. Kim, M.B. Uddin, J.H. Kim, C.Y. Hewawaduge, Z. Ferdowsi, M.H. Sung, C.J. Kim, J.S. Lee, Mucosal vaccination of conserved SM2, HA2 and cholera toxin subunit A1 (CTA1) fusion protein with poly gamma-glutamate/chitosan nanoparticles (PC NPs) induces protection against divergent influenza subtypes, Vet. Microbiol. 201 (2017) 240–251.

[82] M. Singh, M. Briones, D.T. O'Hagan, A novel bioadhesive intranasal delivery system for inactivated influenza vaccines, J. Control. Release 70 (2001) 267–276.

[83] Y. Fan, P. Sahdev, L.J. Ochyl, J. Akerberg, J.J. Moon, Cationic liposome-hyaluronic acid hybrid nanoparticles for intranasal vaccination with subunit antigens, J. Control. Release 208 (2015) 121–129.

[84] T. Nochi, Y. Yuki, H. Takahashi, S. Sawada, M. Mejima, T. Kohda, N. Harada, I.G. Kong, A. Sato, N. Kataoka, D. Tokuhara, S. Kurokawa, Y. Takahashi, H. Tsukada, S. Kozaki, K. Akiyoshi, H. Kiyono, Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines, Nat. Mater. 9 (2010) 572–578.

[85] Y. Fukuyama, Y. Yuki, Y. Katakai, N. Harada, H. Takahashi, S. Takeda, M. Mejima, S. Joo, S. Kurokawa, S. Sawada, H. Shibata, E.J. Park, K. Fujihashi, D.E. Briles, Y. Yasutomí, H. Tsukada, K. Akiyoshi, H. Kiyono, Nanogel-based pneumococcal surface protein A nasal vaccine induces microRNA-associated Th17 cell responses with neutralizing antibodies against Streptococcus pneumoniae in macaques, Mucosal Immunol. 8 (2015) 1144–1153.

[86] D. Nagatomo, M. Tanai, H. Ariyasu, M. Taniguchi, M. Aga, T. Ariyasu, T. Ohta, S. Fukuda, Cholesteryl pullulan encapsulated TNF-alpha nanoparticles are an effective mucosal vaccine adjuvant against influenza virus, Biomed. Res. Int. 2015 (2015) 471468.

[87] F. Sarti, G. Perera, F. Hintzen, K. Kotti, V. Karageorgiou, O. Kammona, C. Kiparissides, A. Bernkop-Schnurch, In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A, Biomaterials 32 (2011) 4052–4057.

[88] F. Khademi, M. Derakhshan, A. Yousefi-Avarvand, A. Najafi, M. Tafaghodi, A novel antigen of Mycobacterium tuberculosis and MPLA adjuvant co-entrapped into PLGA:DDA hybrid nanoparticles stimulates mucosal and systemic immunity, Microb. Pathog. 125 (2018) 507–513.

[89] Z. Tan, W. Liu, H. Liu, C. Li, Y. Zhang, X. Meng, T. Tang, T. Xi, Y. Xing, Oral Helicobacter pylori vaccine-encapsulated acid-resistant HP55/PLGA nanoparticles promote immune protection, Eur. J. Pharm. Biopharm. 111 (2017) 33–43.

[90] Q. Zhu, J. Talton, G. Zhang, T. Cunningham, Z. Wang, R.C. Waters, J. Kirk, B. Eppler, D.M. Klinman, Y. Sui, S. Gagnon, I.M. Belyakov, R.J. Mumper, J.A. Berzofsky, Large intestine-targeted, nanoparticle-releasing oral vaccine to control genitorectal viral infection, Nat. Med. 18 (2012) 1291–1296.

[91] A.K. Jain, A.K. Goyal, N. Mishra, B. Vaidya, S. Mangal, S.P. Vyas, PEG-PLA-PEG block copolymeric nanoparticles for oral immunization against hepatitis B, Int. J. Pharm. 387 (2010) 253–262.

[92] L. Song, D. Xiong, H. Song, L. Wu, M. Zhang, X. Kang, Z. Pan, X. Jiao, Mucosal and systemic immune responses to influenza H7N9 antigen HA1-2 Co-delivered intranasally with flagellin or polyethyleneimine in mice and chickens, Front. Immunol. 8 (2017) 326.

[93] Y. Jiang, M. Li, Z. Zhang, T. Gong, X. Sun, Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants, Pharm. Res. 31 (2014) 2748–2761.
[94] J.F. Mann, P.F. McKay, S. Arokiasamy, R.K. Patel, K. Klein, R.J. Shattock, Pulmonary delivery of DNA vaccine constructs using deacylated PEI elicits immune responses and protects against viral challenge infection, J. Control. Release 170 (2013) 452–459.

[95] S. Jesus, E. Soares, J. Costa, G. Borchard, O. Borges, Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-epsilon-caprolactone based nanoparticles, Int. J. Pharm. 504 (2016) 59–69.

[96] S. Jesus, E. Soares, O. Borges, Poly-epsilon-caprolactone/chitosan and chitosan particles: two recombinant antigen delivery systems for intranasal vaccination, Methods Mol. Biol. 1404 (2016) 697–713.

[97] Y. Li, M. Li, T. Gong, Z. Zhang, X. Sun, Antigen-loaded polymeric hybrid micelles elicit strong mucosal and systemic immune responses after intranasal administration, J. Control. Release 262 (2017) 151–158.

[98] H.F. Florindo, S. Pandit, L. Lacerda, L.M. Goncalves, H.O. Alpar, A.J. Almeida, The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-epsilon-caprolactone-based nanoparticles, Biomaterials 30 (2009) 879–891.

[99] A. Stano, A.J. van der Vlies, M.M. Martino, M.A. Swartz, J.A. Hubbell, E. Simeoni, PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration, Vaccine 29 (2011) 804–812.

[100] C. Nembrini, A. Stano, K.Y. Dane, M. Ballester, A.J. van der Vlies, B.J. Marsland, M.A. Swartz, J.A. Hubbell, Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination, Proc. Natl. Acad. Sci. U. S. A. 108 (2011) E989–E997.

[101] R.A. Rodriguez-Fonseca, M. Bello, M.A. de Los Munoz-Fernandez, J. Luis Jimenez, S. Rojas-Hernandez, M.J. Fragoso-Vazquez, M. Gutierrez-Sanchez, J. Rodrigues, N. Cayetano-Castro, R. Borja-Urby, O. Rodriguez-Cortes, J. Garcia-Machorro, J. Correa-Basurto, In silico search, chemical characterization and immunogenic evaluation of amino-terminated G4-PAMAM-HIV peptide complexes using three-dimensional models of the HIV-1 gp120 protein, Colloids Surf. B: Biointerfaces 177 (2019) 77–93.

[102] F. Rose, J.E. Wern, F. Gavins, P. Andersen, F. Folkmann, C. Foged, A strong adjuvant based on glycol-chitosan-coated lipid-polymer hybrid nanoparticles potentiates mucosal immune responses against the recombinant Chlamydia trachomatis fusion antigen CTH522, J. Control. Release 271 (2018) 88–97.

[103] X. Su, J. Fricke, D.G. Kavanagh, D.J. Irvine, In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles, Mol. Pharm. 8 (2011) 774–787.

[104] M. Bomsel, D. Tudor, D. Drillet, A. Alfsen, Y. Ganor, M.G. Roger, N. Mouz, M. Amacker, A. Chalifour, L. Diomed, G. Devillier, Z. Cong, Q. Wei, H. Gao, C. Qin, G.B. Yang, R. Zurbriggen, L. Lopalo, S. Fleury, Immunization with HIV-1 gp41 sub-unit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges, Immunity 34 (2011) 269–280.

[105] M. Shafique, T. Meijerhof, J. Wilschut, A. de Haan, Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses, PLoS One 8 (2013) e61287.

[106] T. Ebensen, J. Debarry, G.K. Pedersen, P. Blazejewska, S. Weissmann, K. Schulze, K.C. McCullough, R.J. Cox, C.A. Guzman, Mucosal administration of cycle-di-nucleotide-adjuvanted virosomes efficiently induces protection against influenza H5N1 in mice, Front. Immunol. 8 (2017) 1223.
Nanoparticles for mucosal vaccine delivery

[107] F. Pigny, A. Lassus, J. Terrettaz, F. Tranquart, B. Corthesy, G. Bioley, Intranasal vaccination with salmonella-derived serodominant secreted effector protein B associated with gas-filled microbubbles partially protects against gut infection in mice, J. Infect. Dis. 214 (2016) 438–446.

[108] B. Corthesy, G. Bioley, Therapeutic intranasal instillation of allergen-loaded microbubbles suppresses experimental allergic asthma in mice, Biomaterials 142 (2017) 41–51.

[109] N. Benne, J. van Duijn, J. Kuiper, W. Jiskoot, B. Slutter, Orchestrating immune responses: how size, shape and rigidity affect the immunogenicity of particulate vaccines, J. Control. Release 234 (2016) 124–134.

[110] K. Higashisaka, K. Nagano, Y. Yoshioka, Y. Tsutsui, Nano-safety research: examining the associations among the biological effects of nanoparticles and their physicochemical properties and kinetics, Biol. Pharm. Bull. 40 (2017) 243–248.

[111] R.A. Meyer, J.C. Sunshine, K. Perica, A.K. Kosmides, K. Aje, J.P. Schneck, J.J. Green, Biodegradable nanoellipsoidal artificial antigen presenting cells for antigen specific T-cell activation, Small 11 (2015) 1519–1525.

[112] J.A. Champion, S. Mitragotri, Shape induced inhibition of phagocytosis of polymer particles, Pharm. Res. 26 (2009) 244–249.

[113] X. Duan, Y. Li, Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking, Small 9 (2013) 1521–1532.

[114] C.L. Hardy, J.S. Lemasurier, R. Mohamud, J. Yao, S.D. Xiang, J.M. Rolland, R.E. O’Hehir, M. Plebanski, Differential uptake of nanoparticles and microparticles by pulmonary APC subsets induces discrete immunological imprints, J. Immunol. 191 (2013) 5278–5290.

[115] S. Kumar, A.C. Anselmo, A. Banerjee, M. Zakrawsky, S. Mitragotri, Shape and size-dependent immune response to antigen-carrying nanoparticles, J. Control. Release 220 (2015) 141–148.

[116] Y. Wen, A. Waltman, H. Han, J.H. Collier, Switching the immunogenicity of peptide assemblies using surface properties, ACS Nano 10 (2016) 9274–9286.

[117] N.A. Hotaling, R.D. Cummings, D.M. Ratner, J.E. Babensee, Molecular factors in dendritic cell responses to adsorbed glycoconjugates, Biomaterials 35 (2014) 5862–5874.

[118] S.D. Li, L. Huang, Nanoparticles evading the reticuloendothelial system: role of the supported bilayer, Biochim. Biophys. Acta 1788 (2009) 2259–2266.

[119] R.A. Petros, J.M. DeSimone, Strategies in the design of nanoparticles for therapeutic applications, Nat. Rev. Drug Discov. 9 (2010) 615–627.

[120] J.J.F. Verhoef, A.M. de Groot, M. van Moorsel, J. Ritsema, N. Beztinna, C. Maas, H. Schellekens, Iron nanomedicines induce Toll-like receptor activation, cytokine production and complement activation, Biomaterials 119 (2017) 68–77.

[121] S.P. Vyas, P.N. Gupta, Implication of nanoparticles/microparticles in mucosal vaccine delivery, Expert Rev. Vaccines 6 (2007) 401–418.

[122] H.K. Makadia, S.J. Siegel, Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier, Polymers (Basel) 3 (2011) 1377–1397.

[123] Y. Jiao, X. Pang, M. Liu, B. Zhang, L. Li, G. Zhai, Recent progresses in bioadhesive micropsheres via transmucosal administration, Colloids Surf. B: Biointerfaces 140 (2016) 361–372.

[124] V. Bernasconi, K. Norling, M. Bally, F. Hook, N.Y. Lycke, Mucosal vaccine development based on liposome technology, J Immunol Res 2016 (2016) 5482087.

[125] R. Nahire, R. Hossain, R. Patel, S. Paul, V. Meghnni, A.H. Ambre, K.N. Gange, K.S. Katti, E. Leclerc, D.K. Srivastava, K. Sarkar, S. Mallik, pH-triggered echogenicity and contents release from liposomes, Mol. Pharm. 11 (2014) 4059–4068.
Nanoengineered Biomaterials for Advanced Drug Delivery

[126] A.K. Verma, S. Sharma, P. Gupta, D. Singodia, S. Kansal, V. Sharma, P.R. Mishra, Vitamin B12 grafted layer-by-layer liposomes bearing HBsAg facilitate oral immunization: effect of modulated biomechanical properties, Mol. Pharm. 13 (2016) 2531–2542.

[127] N. Wang, T. Wang, M. Zhang, R. Chen, R. Niu, Y. Deng, Mannose derivative and lipid A dually decorated cationic liposomes as an effective cold chain free oral mucosal vaccine adjuvant-delivery system, Eur. J. Pharm. Biopharm. 88 (2014) 194–206.

[128] B. Corthesy, G. Bioley, Lipid-based particles: versatile delivery systems for mucosal vaccination against infection, Front. Immunol. 9 (2018) 431.

[129] R. Tada, A. Hidaka, H. Kiyono, J. Kunisawa, Y. Aramaki, Intranasal administration of cationic liposomes enhanced granulocyte-macrophage colony-stimulating factor expression and this expression is dispensable for mucosal adjuvant activity, BMC. Res. Notes 11 (2018) 472.

[130] R. Tada, S. Muto, T. Iwata, A. Hidaka, H. Kiyono, J. Kunisawa, Y. Aramaki, Attachment of class B CpG ODN onto DOTAP/DC-chol lipidosome in nasal vaccine formulations augments antigen-specific immune responses in mice, BMC. Res. Notes 10 (2017) 68.

[131] R. Tada, A. Hidaka, N. Iwase, S. Takahashi, Y. Yamakita, T. Iwata, S. Muto, E. Sato, N. Takayama, E. Honjo, H. Kiyono, J. Kunisawa, Y. Aramaki, Intranasal immunization with DOTAP cationic liposomes combined with DC-cholesterol induces potent antigen-specific mucosal and systemic immune responses in mice, PLoS One 10 (2015) e0139785.

[132] D. Christensen, J.P. Christensen, K.S. Korsholm, L.K. Isling, K. Erneholm, A.R. Thomasen, P. Andersen, Seasonal influenza split vaccines confer partial cross-protection against heterologous influenza virus in ferrets when combined with the CAF01 adjuvant, Front. Immunol. 8 (2017) 1928.

[133] E. Lorenzen, F. Follmann, S. Boje, K. Erneholm, A.W. Olsen, J.S. Agerholm, G. Jungersen, P. Andersen, Intramuscular priming and intranasal boosting induce strong genital immunity through secretory IgA in minipigs infected with chlamydia trachomatis, Front. Immunol. 6 (2015) 628.

[134] P.L. Jiang, H.J. Lin, H.W. Wang, W.Y. Tsai, S.F. Lin, M.Y. Chien, P.H. Liang, Y.Y. Huang, D.Z. Liu, Galactosylated lipidosome as a dendritic cell-targeted mucosal vaccine for inducing protective anti-tumor immunity, Acta Biomater. 11 (2015) 356–367.

[135] S. Minato, K. Iwanaga, M. Kakemi, S. Yamashita, N. Oku, Application of polyethylene glycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity, J. Control. Release 89 (2003) 189–197.

[136] Y. Shimizu, T. Iwasaki, T. Tajima, E. Yuba, K. Kono, S. Watarai, Induction of antibody response in the oral cavity of dogs following intraocular (eye drop) immunization with Porphyromonas gingivalis cell lysate incorporated in pH-sensitive fusogenic polymer-modified liposomes, J. Vet. Med. Sci. 79 (2017) 290–298.

[137] S. Watarai, T. Iwase, T. Tajima, E. Yuba, K. Kono, Y. Sekiya, Application of pH-sensitive fusogenic polymer-modified liposomes for development of mucosal vaccines, Vet. Immunol. Immunopathol. 158 (2014) 62–72.

[138] Y. Yoshizaki, E. Yuba, N. Sakaguchi, K. Koiwai, A. Harada, K. Kono, pH-sensitive polymer-modified liposome-based immunity-inducing system: effects of inclusion of cationic lipid and CpG-DNA, Biomaterials 141 (2017) 272–283.

[139] J.J. Moon, H. Suh, A. Bershteyn, M.T. Stephan, H. Liu, B. Huang, M. Sohail, S. Luo, S.H. Um, H. Khant, J.T. Goodwin, J. Ramos, W. Chiu, D.J. Irvine, Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses, Nat. Mater. 10 (2011) 243–251.
Nanoparticles for mucosal vaccine delivery

[140] S. Gordon, K. Young, R. Wilson, S. Rizwan, R. Kemp, T. Rades, S. Hook, Chitosan hydrogels containing liposomes and cubosomes as particulate sustained release vaccine delivery systems, J. Liposome Res. 22 (2012) 193–204.

[141] Y. Singh, J.G. Meher, K. Raval, F.A. Khan, M. Chaurasia, N.K. Jain, M.K. Chourasia, Nanoemulsion: concepts, development and applications in drug delivery, J. Control. Release 252 (2017) 28–49.

[142] P.E. Makidon, A.U. Bielinska, S.S. Nigavekar, K.W. Janczak, J. Knowlton, A.J. Scott, N. Mank, Z. Cao, S. Rathinavelu, M.R. Beer, J.E. Wilkinson, L.P. Blanco, J.J. Landers, J.R. Baker Jr., Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine, PLoS One 3 (2008) e2954.

[143] S.T. Schmidt, M.A. Neustrup, S. Harloff-Helleberg, K.S. Korsholm, T. Rades, P. Andersen, D. Christensen, C. Foged, Systematic investigation of the role of surfactant composition and choice of oil: design of a nanoemulsion-based adjuvant inducing concomitant humoral and CD4(+) T-cell responses, Pharm. Res. 34 (2017) 1716–1727.

[144] R.N. Lodaya, L.A. Brito, T.Y.H. Wu, A.T. Miller, G.R. Otten, M. Singh, D.T. O’Hagan, Stable nanoemulsions for the delivery of small molecule immune potentiators, J. Pharm. Sci. 107 (2018) 2310–2314.

[145] A.U. Bielinska, K.W. Janczak, J.J. Landers, P. Makidon, L.E. Sower, J.W. Peterson, J.R. Baker Jr., Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis sporulation, Infect. Immun. 75 (2007) 4020–4029.

[146] W.M. Bogers, H. Oostermeijer, P. Mooij, G. Koopman, E.J. Verschoor, D. Davis, J.B. Ulmer, L.A. Brito, Y. Cu, K. Banerjee, G.R. Otten, B. Burke, A. Dey, J.L. Heeney, X. Shen, G.D. Tomaras, C. Labranche, D.C. Montefiori, H.X. Liao, B. Haynes, A.J. Geall, S.W. Barnett, Potent immune responses in rhesus macaques induced by non-viral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion, J. Infect. Dis. 211 (2015) 947–955.

[147] M. Brazzoli, D. Magini, A. Bonci, S. Buccato, C. Giovani, R. Kratzer, V. Zurli, S. Mangiavacchi, D. Casini, L.M. Brito, E. De Gregorio, P.W. Mason, J.B. Ulmer, A.J. Geall, S. Bertholet, Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin, J. Virol. 90 (2016) 332–344.

[148] K. Lovgren, B. Morein, The requirement of lipids for the formation of immunostimulating complexes (iscoms), Biotechnol. Appl. Biochem. 10 (1988) 161–172.

[149] H.X. Sun, Y. Xie, Y.P. Ye, ISCOMs and ISCOMATRIX, Vaccine 27 (2009) 4388–4401.

[150] A.M. Mowat, A.M. Donachie, S. Jegawall, K. Schon, B. Lowenadler, K. Dalsgaard, P. Kaastrup, N. Lycke, CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen, J. Immunol. 167 (2001) 3398–3405.

[151] E. Marks, A. Helgeby, J.O. Andersson, K. Schon, N.Y. Lycke, CD4(+) T-cell immunity in the female genital tract is critically dependent on local mucosal immunization, Eur. J. Immunol. 41 (2011) 2642–2653.

[152] R.S. Pandey, V.K. Dixit, Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B, J. Drug Target. 18 (2010) 282–291.

[153] S. Kodama, T. Hirano, K. Noda, S. Umemoto, M. Suzuki, Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzae-specific long-term mucosal immune responses in the nasopharynx, Vaccine 29 (2011) 1881–1890.
S. Pabreja, T. Garg, G. Rath, A.K. Goyal, Mucosal vaccination against tuberculosis using Ag85A-loaded immunostimulating complexes, Artif. Cells Nanomed. Biotechnol. 44 (2016) 532–539.

A.A. Timothy, A. Tokanovic, K.J. Snibson, S.J. Edwards, M.J. Pearse, J.P. Scheerlinck, P. Sutton, ISCOMATRIX adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza, Hum. Vaccin. Immunother. 11 (2015) 377–385.

R.C. Cheung, T.B. Ng, J.H. Wong, W.Y. Chan, Chitosan: an update on potential biomedical and pharmaceutical applications, Mar. Drugs 13 (2015) 5156–5186.

M.S. Riaz Rajoka, L. Zhao, H.M. Mehwish, Y. Wu, S. Mahmood, Chitosan and its derivatives: synthesis, biotechnological applications, and future challenges, Appl. Microbiol. Biotechnol. (2019).

M.E. Mummert, Immunologic roles of hyaluronan, Immunol. Res. 31 (2005) 189–206.

A.L. Silva, P.C. Soema, B. Slutter, F. Ossendorp, W. Jiskoot, PLGA particulate delivery systems for subunit vaccines: linking particle properties to immunogenicity, Hum. Vaccin. Immunother. 12 (2016) 1056–1069.

S.L. Demento, W. Cui, J.M. Criscione, E. Stern, J. Tulipan, S.M. Kaech, J. Fahmy, Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype, Biomaterials 33 (2012) 4957–4964.

T. Ma, L. Wang, T. Yang, G. Ma, S. Wang, M-cell targeted polymeric lipid nanoparticles containing a Toll-like receptor agonist to boost oral immunity, Int. J. Pharm. 473 (2014) 296–303.

S.M. Singh, T.N. Alkie, E. Nagy, R.R. Kulkarni, D.C. Hodgins, S. Sharif, Delivery of an inactivated avian influenza virus adjuvanted with poly(D,L-lactic-co-glycolic acid) encapsulated CpG ODN induces protective immune responses in chickens, Vaccine 34 (2016) 4807–4813.

C. Primard, J. Poecheim, S. Heuking, E. Sublet, F. Esmaeili, G. Borchard, Multifunctional PLGA-based nanoparticles encapsulating simultaneously hydrophilic antigen and hydrophobic immunomodulator for mucosal immunization, Mol. Pharm. 10 (2013) 2996–3004.

S.P. Kasturi, I. Skountzou, R.A. Albrecht, D. Koutsonanos, T. Hua, H.I. Nakaya, R. Ravindran, S. Stewart, M. Alam, M. Kwissa, F. Villinger, N. Murthy, J. Steel, J. Jacob, R.J. Hogan, A. Garcia-Sastre, R. Comps, B. Pulendran, Programming the magnitude and persistence of antibody responses with innate immunity, Nature 470 (2011) 543–547.

S.P. Kasturi, P.A. Kozlowski, H.I. Nakaya, M.C. Burger, P. Russo, M. Pham, Y. Kovalenko, E.L. Silveira, C. Havenar-Daughton, S.L. Burton, K.M. Kilgore, M.J. Johnson, R. Nabi, T. Legere, Z.J. Sher, X. Chen, R.R. Amara, E. Hunter, S.E. Bosingher, P. Spearman, S. Crotty, F. Villinger, C.A. Derdeyn, J. Wrammert, B. Pulendran, Adjuvantaing a simian immunodeficiency virus vaccine with toll-like receptor ligands encapsulated in nanoparticles induces persistent antibody responses and enhanced protection in TRIM5alpha restrictive macaques, J. Virol. 91 (2017).

Q. Zhu, C. Egelston, S. Gagnon, Y. Sui, I.M. Belyakov, D.M. Klinman, J.A. Berzofsky, Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice, J. Clin. Invest. 120 (2010) 607–616.

T.E. Rajapaksa, M. Stover-Hamer, X. Fernandez, H.A. Eckelhoefer, D.D. Lo, Claudin 4-targeted protein incorporated into PLGA nanoparticles can mediate M cell targeted delivery, J. Control. Release 142 (2010) 196–205.

M. Garinot, V. Fievez, V. Pourcelle, F. Stoffelbach, A. des Rieux, L. Plapied, I. Theate, H. Freichels, C. Jerome, J. Marchand-Brynaert, Y.J. Schneider, V. Preat, PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination, J. Control. Release 120 (2007) 195–204.
Nanoparticles for mucosal vaccine delivery

[169] A. Vila, A. Sanchez, C. Evora, I. Soriano, J.L. Vila Jato, M.J. Alonso, PEG-PLA nanoparticles as carriers for nasal vaccine delivery, J. Aerosol Med. 17 (2004) 174–185.

[170] V. Pavot, N. Climent, N. Rochereau, F. Garcia, C. Genin, G. Tiraby, F. Vernejoul, E. Perouzel, T. Lioux, B. Verrier, S. Paul, Directing vaccine immune responses to mucosa by nanosized particulate carriers encapsulating NOD ligands, Biomaterials 75 (2016) 327–339.

[171] J. Resseguier, E. Delaune, A.L. Coolen, J.P. Levraud, P. Boudinot, D. Le Guellec, B. Verrier, Specific and efficient uptake of surfactant-free poly(lactic acid) nanovaccine vehicles by mucosal dendritic cells in adult zebrafish after bath immersion, Front. Immunol. 8 (2017) 190.

[172] C. Shen, J. Li, Y. Zhang, Y. Li, G. Shen, J. Zhu, J. Tao, Polyethyleneimine-based micro/nanoparticles as vaccine adjuvants, Int. J. Nanomedicine 12 (2017) 5443–5460.

[173] T. Merdan, K. Kunath, D. Fischer, J. Kopecek, T. Kissel, Intracellular processing of poly(ethylene imine)/ribozyme complexes can be observed in living cells by using confocal laser scanning microscopy and inhibitor experiments, Pharm. Res. 19 (2002) 140–146.

[174] J. Chen, Z. Li, H. Huang, Y. Yang, Q. Ding, J. Mai, W. Guo, Y. Xu, Improved antigen cross-presentation by polyethyleneimine-based nanoparticles, Int. J. Nanomedicine 6 (2011) 77–84.

[175] J. Firdous, M.A. Islam, S.M. Park, I.S. Cheon, B.S. Shim, H.S. Yoon, M. Song, J. Chang, Y.J. Choi, Y.M. Park, D. Boraschi, S.H. Han, C.S. Cho, C.H. Yun, Induction of long-term immunity against respiratory syncytial virus glycoprotein by an osmotic polymeric nanocarrier, Acta Biomater. 10 (2014) 4606–4617.

[176] F. Wegmann, K.H. Gartlan, A.M. Harandi, S.A. Brinckmann, M. Coccia, W.R. Hillson, W.L. Kok, S. Cole, L.P. Ho, T. Lambe, M. Puthia, C. Svanborg, E.M. Scherer, G. Krashias, A. Williams, J.N. Blattman, P.D. Greenberg, R.A. Flavell, A.E. Moghaddam, N.C. Sheppard, Q.J. Sattentau, Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens, Nat. Biotechnol. 30 (2012) 883–888.

[177] B.S. Shim, S.M. Park, J.S. Quan, D. Jere, H. Chu, M.K. Song, D.W. Kim, Y.S. Jang, M.S. Yang, S.H. Han, Y.H. Park, C.S. Cho, C.H. Yun, Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses, BMC Immunol. 11 (2010) 65.

[178] M. Li, M. Zhao, Y. Fu, Y. Li, T. Gong, Z. Zhang, X. Sun, Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways, J. Control. Release 228 (2016) 9–19.

[179] M. Li, Y. Li, K. Peng, Y. Wang, T. Gong, Z. Zhang, Q. He, X. Sun, Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses, Acta Biomater. 64 (2017) 237–248.

[180] Y.H. Kim, J.H. Park, M. Lee, Y.H. Kim, T.G. Park, S.W. Kim, Polyethyleneimine with acid-labile linkages as a biodegradable gene carrier, J. Control. Release 103 (2005) 209–219.

[181] J.L. Santos, D. Pandita, J. Rodrigues, A.P. Pego, P.L. Granja, H. Tomas, Non-viral gene delivery to mesenchymal stem cells: methods, strategies and application in bone tissue engineering and regeneration, Curr. Gene Ther. 11 (2011) 46–57.

[182] W. Wang, M. Balk, Z. Deng, C. Wischke, M. Gossen, M. Behl, N. Ma, A. Lendlein, Engineering biodegradable micelles of polyethylenimine-based amphiphilic block copolymers for efficient DNA and siRNA delivery, J. Control. Release 242 (2016) 71–79.

[183] M.A. Benoit, B. Baras, J. Gillard, Preparation and characterization of protein-loaded poly(epsilon-caprolactone) microparticles for oral vaccine delivery, Int. J. Pharm. 184 (1999) 73–84.
[184] J. Singh, S. Pandit, V.W. Bramwell, H.O. Alpar, Diphtheria toxoid loaded poly-(epsilon-caprolactone) nanoparticles as mucosal vaccine delivery systems, Methods 38 (2006) 96–105.

[185] S.T. Reddy, A. Rehor, H.G. Schmoekel, J.A. Hubbell, M.A. Swartz, In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles, J. Control. Release 112 (2006) 26–34.

[186] S.T. Reddy, A.J. van der Vlies, E. Simeoni, V. Angeli, G.J. Randolph, C.P. O’Neil, L.K. Lee, M.A. Swartz, J.A. Hubbell, Exploiting lymphatic transport and complement activation in nanoparticle vaccines, Nat. Biotechnol. 25 (2007) 1159–1164.

[187] A. Stano, C. Nembrini, M.A. Swartz, J.A. Hubbell, E. Simeoni, Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization, Vaccine 30 (2012) 7541–7546.

[188] A.P. Sherje, M. Jadhav, B.R. Dravyakar, D. Kadam, Dendrimers: a versatile nanocarrier for drug delivery and targeting, Int. J. Pharm. 548 (2018) 707–720.

[189] S. Misumi, M. Masuyama, N. Takamune, D. Nakayama, R. Mitsumata, H. Matsumoto, N. Urata, Y. Takahashi, A. Muneoka, T. Sukamoto, K. Fukuzaki, S. Shoji, Targeted delivery of immunogen to primate m cells with tetragalloyl lysine dendrimer, J. Immunol. 182 (2009) 6061–6070.

[190] R.I.C. Bose, R. Ravikumar, V. Karuppagounder, D. Bennet, S. Rangasamy, R.A. Thandavarayan, Lipid-polymer hybrid nanoparticle-mediated therapeutics delivery: advances and challenges, Drug Discov. Today 22 (2017) 1258–1265.

[191] K. Hadinoto, A. Sundaresan, W.S. Cheow, Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review, Eur. J. Pharm. Biopharm. 85 (2013) 427–443.

[192] F. Rose, J.E. Wern, P.T. Ingvarsson, M. van de Weert, P. Andersen, F. Follmann, C. Foged, Engineering of a novel adjuvant based on lipid-polymer hybrid nanoparticles: a quality-by-design approach, J. Control. Release 210 (2015) 48–57.

[193] Z. Zhao, Y. Hu, T. Harmon, P. Pentel, M. Ehrich, C. Zhang, Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: a focus on hapten localization, Biomaterials 138 (2017) 46–56.

[194] K. Schneider-Ohrum, T.M. Ross, Virus-like particles for antigen delivery at mucosal surfaces, Curr. Top. Microbiol. Immunol. 354 (2012) 53–73.

[195] Y. Gao, C. Wijewardhana, J.F.S. Mann, Virus-like particle, liposome, and polymeric particle-based vaccines against HIV-1, Front. Immunol. 9 (2018) 345.

[196] C. Moser, M. Muller, M.D. Kaeser, U. Weydemann, M. Amacker, Influenza virosomes as vaccine adjuvant and carrier system, Expert Rev. Vaccines 12 (2013) 779–791.

[197] P.C. Soema, S.K. Rosendahl Huber, G.J. Willems, W. Jiskoot, G.F. Kersten, J.P. Amorij, Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine, Pharm. Res. 32 (2015) 1505–1515.

[198] G. Leroux-Roels, C. Maes, F. Clement, F. van Engelenburg, M. van den Dobbelsteen, M. Adler, M. Amacker, L. Lopalco, M. Bomsel, A. Chalifour, S. Fleury, Randomized phase I: safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV-1 Gp41 P1 peptide on virosomes, PLoS One 8 (2013) e55438.

[199] M.G. Cusi, R. Zurbriggen, M. Valassina, S. Bianchi, P. Durrer, P.E. Valensin, M. Donati, R. Gluck, Intranasal immunization with mumps virus DNA vaccine delivered by influenza virosomes elicits mucosal and systemic immunity, Virology 277 (2000) 111–118.

[200] T. Gargett, B. Grubor-Bauk, D. Miller, T. Garrod, S. Yu, S. Wesselingh, A. Suhrbier, E.J. Gowans, Increase in DNA vaccine efficacy by virosole delivery and co-expression of a cytolgytic protein, Clin. Transl. Immunol. 3 (2014) e18.
Nanoparticles for mucosal vaccine delivery

[201] M.G. Cusi, C. Terrosi, G.G. Savellini, G. Di Genova, R. Zurbriggen, P. Correale, Efficient delivery of DNA to dendritic cells mediated by influenza virosomes, Vaccine 22 (2004) 735–739.

[202] J.R. Lindner, Microbubbles in medical imaging: current applications and future directions, Nat. Rev. Drug Discov. 3 (2004) 527–532.

[203] B. Corthesy, G. Bioley, Gas-filled microbubbles: novel mucosal antigen-delivery system for induction of anti-pathogen’s immune responses in the gut, Gut Microbes 8 (2017) 511–519.

[204] C.A. Sennoga, E. Kanbar, L. Auboire, P.A. Dujardin, D. Fouan, J.M. Escoffre, A. Bouakaz, Microbubble-mediated ultrasound drug-delivery and therapeutic monitoring, Exp. Opin. Drug Deliv. 14 (2017) 1031–1043.

[205] A. Delalande, C. Bastie, L. Pigeon, S. Manta, M. Lebrertre, N. Mignet, P. Midoux, C. Pichon, Cationic gas-filled microbubbles for ultrasound-based nucleic acids delivery, Biosci. Rep. 37 (2017).

[206] B.L. Helfield, X. Chen, B. Qin, S.C. Watkins, F.S. Villanueva, Mechanistic insight into sonoporation with ultrasound-stimulated polymer microbubbles, Ultrasound Med. Biol. 43 (2017) 2678–2689.

[207] G. Bioley, P. Bussat, A. Lassus, M. Schneider, J. Terrettaz, B. Corthesy, The phagocytosis of gas-filled microbubbles by human and murine antigen-presenting cells, Biomaterials 33 (2012) 333–342.

[208] G. Bioley, A. Lassus, P. Bussat, J. Terrettaz, F. Tranquart, B. Corthesy, Gas-filled microbubble-mediated delivery of antigen and the induction of immune responses, Biomaterials 33 (2012) 5935–5946.

[209] C. Foged, Thermostable subunit vaccines for pulmonary delivery: how close are we? Curr. Pharm. Des. 22 (2016) 2561–2576.

[210] Y. Jia, L. Krishnan, A. Omri, Nasal and pulmonary vaccine delivery using particulate carriers, Exp. Opin. Drug Deliv. 12 (2015) 993–1008.

[211] P.T. Ingvarsson, M. Yang, H. Mulvad, H.M. Nielsen, J. Rantanen, C. Foged, Engineering of an inhalable DDA/TDB liposomal adjuvant: a quality-by-design approach towards optimization of the spray drying process, Pharm. Res. 30 (2013) 2772–2784.

[212] P.T. Ingvarsson, S.T. Schmidt, D. Christensen, N.B. Larsen, W.L. Hinrichs, P. Andersen, J. Rantanen, H.M. Nielsen, M. Yang, C. Foged, Designing CAF-adjuvanted dry powder vaccines: spray drying preserves the adjuvant activity of CAF01, J. Control. Release 167 (2013) 256–264.

[213] A. Thakur, P.T. Ingvarsson, S.T. Schmidt, F. Rose, P. Andersen, D. Christensen, C. Foged, Immunological and physical evaluation of the multistage tuberculosis subunit vaccine candidate H56/CAF01 formulated as a spray-dried powder, Vaccine 36 (2018) 3331–3339.

[214] T. Sou, D.A. Morton, M. Williamson, E.N. Meeusen, L.M. Kaminskas, M.P. McIntosh, Spray-dried influenza antigen with trehalose and leucine produces an aerosolizable powder vaccine formulation that induces strong systemic and mucosal immunity after pulmonary administration, J. Aerosol Med. Pulm. Drug Deliv. 28 (2015) 361–371.

[215] G. Kanojia, R.H.M. Raemen, L. van der Maas, T.H.E. Bindels, E. van Riet, B. Metz, P.C. Soema, R. Ten Have, H.W. Frijlink, J.P. Amorij, G.F.A. Kersten, Development of a thermostable spray dried outer membrane vesicle pertussis vaccine for pulmonary immunization, J. Control. Release 286 (2018) 167–178.

[216] P. Muttil, B. Pulliam, L. Garcia-Contreras, J.K. Fallon, C. Wang, A.J. Hickey, D.A. Edwards, Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses, AAPS J. 12 (2010) 699–707.
Nanoengineered Biomaterials for Advanced Drug Delivery

[217] P. Muttil, C. Prego, L. Garcia-Contreras, B. Pulliam, J.K. Fallon, C. Wang, A.J. Hickey, D. Edwards, Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route, AAPS J. 12 (2010) 330–337.

[218] N.K. Kunda, I.M. Alfaigih, E.N. Miyaji, D.B. Figueiredo, V.M. Goncalves, D.M. Ferreira, S.R. Dennison, S. Somavarapu, G.A. Hutcheon, I.Y. Saleem, Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles, Int. J. Pharm. 495 (2015) 903–912.

[219] R.L. de Swart, C. LiCalsi, A.V. Quirk, G. van Amerongen, V. Nodelman, R. Alcock, S. Yuksel, G.H. Ward, J.G. Hardy, H. Vos, C.L. Witham, C.I. Grainger, T. Kuiken, B.J. Greenspan, T.G. Gard, A.D. Osterhaus, Measles vaccination of macaques by dry powder inhalation, Vaccine 25 (2007) 1183–1190.

[220] Y.L. Wong, S. Sampson, W.A. Germishuizen, S. Goonesekera, G. Caponetti, J. Sadoff, B.R. Bloom, D. Edwards, Drying a tuberculosis vaccine without freezing, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 2591–2595.

[221] L. Garcia-Contreras, Y.L. Wong, P. Muttil, D. Padilla, J. Sadoff, J. Derousse, W.A. Germishuizen, S. Goonesekera, K. Elbert, B.R. Bloom, R. Miller, P.B. Fourie, A. Hickey, D. Edwards, Immunization by a bacterial aerosol, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 4656–4660.

[222] M. Ibrahim, M.K. Hatipoglu, L. Garcia-Contreras, SHetA2 dry powder aerosols for tuberculosis: formulation, design, and optimization using quality by design, Mol. Pharm. 15 (2018) 300–313.

[223] R.M. Kramer, M.C. Archer, M.T. Orr, N. Dubois Cauwelerta, E.A. Beebe, P.D. Huang, Q.M. Dowling, A.M. Schwartz, D.M. Fedor, T.S. Vedvick, C.B. Fox, Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach, Int. J. Nanomedicine 13 (2018) 3689–3711.

[224] G. Kanojia, G.J. Willems, H.W. Frijlink, G.F. Kersten, P.C. Soema, J.P. Amorij, A Design of experiment approach to predict product and process parameters for a spray dried influenza vaccine, Int. J. Pharm. 511 (2016) 1098–1111.

[225] K.K. Sahu, R.S. Pandey, Development and characterization of HBsAg-loaded Eudragit nanoparticles for effective colonic immunization, Pharm. Dev. Technol. 24 (2019) 166–175.

[226] P.L. Ahl, C. Mensch, B. Hu, H. Pixley, L. Zhang, L. Dieter, R. Russell, W.J. Smith, C. Przysiezicki, M. Kosinski, J.T. Blue, Accelerating vaccine formulation development using design of experiment stability studies, J. Pharm. Sci. 105 (2016) 3046–3056.

[227] A. Patel, S.M. Erb, L. Strange, R.S. Shukla, O.S. Kumru, L. Smith, P. Nelson, S.B. Joshi, J.A. Livengood, D.B. Volkin, Combined semi-empirical screening and design of experiments (DOE) approach to identify candidate formulations of a lyophilized live attenuated tetravalent viral vaccine candidate, Vaccine 36 (2018) 3169–3179.

[228] T. Sou, E.N. Meeusen, M. de Veer, D.A. Morton, L.M. Kaminskas, M.P. McIntosh, New developments in dry powder pulmonary vaccine delivery, Trends Biotechnol. 29 (2011) 191–198.

[229] F. Blank, P.A. Stumbles, E. Seydoux, P.G. Holt, A. Fink, B. Rothen-Rutishauser, D.H. Strickland, C. von Garnier, Size-dependent uptake of particles by pulmonary antigen-presenting cell populations and trafficking to regional lymph nodes, Am. J. Respir. Cell Mol. Biol. 49 (2013) 67–77.

[230] T.M. Brenza, L.K. Petersen, Y. Zhang, L.M. Huntimer, A.E. Ramer-Tait, J.M. Hostetter, M.J. Wannemuehler, B. Narasimhan, Pulmonary biodistribution and cellular uptake of intranasally administered monodisperse particles, Pharm. Res. 32 (2015) 1368–1382.
Nanoparticles for mucosal vaccine delivery

[231] C.A. Fromen, G.R. Robbins, T.W. Shen, M.P. Kai, J.P. Ting, J.M. DeSimone, Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization, Proc. Natl. Acad. Sci. U. S. A. 112 (2015) 488–493.

[232] A. Minne, J. Louahed, S. Mehauden, B. Baras, J.C. Renauld, R. Vanbever, The delivery site of a monovalent influenza vaccine within the respiratory tract impacts on the immune response, Immunology 122 (2007) 316–325.

[233] Y. Bhide, J. Tomar, W. Dong, J. de Vries-Idema, H.W. Frijlink, A. Huckriede, W.L.J. Hinrichs, Pulmonary delivery of influenza vaccine formulations in cotton rats: site of deposition plays a minor role in the protective efficacy against clinical isolate of H1N1pdm virus, Drug Deliv. 25 (2018) 533–545.

[234] T.E. Corcoran, Imaging in aerosol medicine, Respir. Care 60 (2015) 850–855. discussion 855-857.

[235] T.C. Carvalho, J.I. Peters, R.O. Williams 3rd., Influence of particle size on regional lung deposition—what evidence is there? Int. J. Pharm. 406 (2011) 1–10.

[236] V. Ilic, V. Dunet, A. Le Pape, M. Buchs, M. Kosinski, A. Bischof Delaloye, S. Gerber, J.O. Prior, SPECT/CT study of bronchial deposition of inhaled particles. A human aerosol vaccination model against HPV, Nuklearmedizin 55 (2016) 203–208.

[237] M. Scarpelli, C. Zahm, S. Perlman, D.G. McNeel, R. Jeraj, G. Liu, FLT PET/CT imaging of metastatic prostate cancer patients treated with pTVG-HP DNA vaccine and pembrolizumab, J. Immunother. Cancer 7 (2019) 23.

[238] E.E. Coates, P.J. Costner, M.C. Nason, D.M. Herrin, S. Conant, P. Herscovitch, U.N. Sarwar, L. Holman, J. Mitchell, G. Yamshchikov, R.A. Koup, B.S. Graham, C.M. Millo, J.E. Ledgerwood, VRC 900 Study Team, Lymph node activation by PET/CT following vaccination with licensed vaccines for human papillomaviruses, Clin. Nucl. Med. 42 (2017) 329–334.

[239] M.L. Tremblay, C. Davis, C.V. Bowen, O. Stanley, C. Parsons, G. Weir, M. Karkada, M.M. Stanford, K.D. Brewer, Using MRI cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine, Magn. Reson. Med. 80 (2018) 304–316.

[240] D.R. DeBay, K.D. Brewer, S.A. LeBlanc, G.M. Weir, M.M. Stanford, M. Mansour, C.V. Bowen, Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines, Mol. Ther. Methods Clin. Dev. 2 (2015) 15048.

[241] A. Thakur, F. Rose, S.R. Ansari, P. Koch, V. Martini, S.L. Ovesen, B. Quistorff, S. Maritim, F. Hyder, P. Andersen, D. Christensen, Y. Mori, Foged, Design of gadoteridol-loaded cationic liposomal adjuvant CAF01 for MRI of lung deposition of intrapulmonary administered particles. Mol. Pharm 16 (11) (2019) 4725–4737, https://doi.org/10.1021/acs.molpharmaceut.9b00908.

[242] K. Thanki, K.G. Blum, A. Thakur, F. Rose, C. Foged, Formulation of RNA interference-based drugs for pulmonary delivery: challenges and opportunities, Ther. Deliv. 9 (2018) 731–749.

[243] M. Morello, C.L. Krone, S. Dickerson, E. Howerth, W.A. Germishuizen, Y.L. Wong, D. Edwards, B.R. Bloom, M.K. Hondalus, Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies, Tuberculosis (Edinb) 89 (2009) 371–377.

[244] A.S. Tyne, J.G. Chan, E.R. Shanahan, I. Atmoussakoto, H.K. Chan, W.J. Britton, N.P. West, TLR2-targeted secreted proteins from Mycobacterium tuberculosis are protective as powdered pulmonary vaccines, Vaccine 31 (2013) 4322–4329.

[245] S.A. Audouy, G. van der Schaaf, W.L. Hinrichs, H.W. Frijlink, J. Wilschut, A. Huckriede, Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization, Vaccine 29 (2011) 4345–4352.
[246] W.F. Tonnis, M. Bagerman, M. Weij, J. Sjollema, H.W. Frijlink, W.L. Hinrichs, A.H. de Boer, A novel aerosol generator for homogenous distribution of powder over the lungs after pulmonary administration to small laboratory animals, Eur. J. Pharm. Biopharm. 88 (2014) 1056–1063.

[247] A. Fioni, E. Selg, V. Cenacchi, F. Acevedo, G. Brogin, P. Gerde, P. Puccini, Investigation of lung pharmacokinetic of the novel PDE4 inhibitor CHF6001 in preclinical models: evaluation of the preciseinhale technology, J. Aerosol Med. Pulm. Drug Deliv. 31 (2018) 61–70.

[248] A.J. Lexmond, S. Keir, W. Terakosolphan, C.P. Page, B. Forbes, A novel method for studying airway hyperresponsiveness in allergic guinea pigs in vivo using the PreciseInhale system for delivery of dry powder aerosols, Drug Deliv. Transl. Res. 8 (2018) 760–769.